



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>6</sup>:C07D 213/65, 213/32, 213/14, A61K  
31/44

A1

(11) International Publication Number:

WO 96/21648

(43) International Publication Date:

18 July 1996 (18.07.96)

(21) International Application Number: PCT/KR96/00005

(22) International Filing Date: 10 January 1996 (10.01.96)

(30) Priority Data:

1995/399	11 January 1995 (11.01.95)	KR
1995/43607	24 November 1995 (24.11.95)	KR

(71) Applicant (for all designated States except US): SAMJIN PHARMACEUTICAL CO., LTD. [KR/KR]; 338-8, Seokyo-dong, Mapo-ku, Seoul 121-210 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHO, Eui-Hwan [KR/KR]; 105-101, Hyundai Apartment, Kaepo 1-dong, Kangnam-ku, Seoul 135-241 (KR). CHUNG, Sun-Gan [KR/KR]; B-106, Seokyo Apartment, 344-1, Seokyo-dong, Mapo-ku, Seoul 121-210 (KR). KIM, Joong-Young [KR/KR]; 6-102, Sinmaetan Apartment, Maetan 3-dong, Paldal-ku, Suwon, Kyungki-do 442-373 (KR). LEE, Sun-Hwan [KR/KR]; 105-403, Daelim Apartment, Dokkok-dong, Songtan, Kyungki-do 459-100 (KR). KWON, Ho-Seok [KR/KR]; 989-17, Inkyeo-dong, Paldal-ku, Suwon, Kyungki-do 442-070 (KR). KIM, Byung-Chul [KR/KR]; 102-412, Ajoo 1st Apartment, Jisan-dong, Songtan, Kyungki-do 459-110 (KR). KONG, Jae-Myeong

[KR/KR]; 168-22, Yuljeon-dong, Jangan-ku, Suwon, Kyungki-do 440-320 (KR). LEE, Jae-Eung [KR/KR]; 390-3, Sinjang 2-dong, Hanam, Kyungki-do 465-032 (KR). KANG, Dong-Wook [KR/KR]; 5-2, Kangnam-dong, Jinju, Kyungsangnam-do 660-250 (KR).

(74) Agent: PARK, Sa, Ryong; 823-5, Yoksam-dong, Kangnam-ku, Seoul 135-080 (KR).

(81) Designated States: AU, BG, BR, CA, CN, CZ, FI, HU, JP, MX, NO, NZ, PL, RO, RU, SG, SK, TR, UA, US, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).


Published

With international search report.

(54) Title: NEW PIPERAZINE DERIVATIVES AND METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME

(57) Abstract

The present invention relates to novel compound of general formula (I) and acid addition salt thereof, wherein  $R_1$  and  $R_2$  are independently hydrogen,  $C_1$ - $C_8$  alkyl or optionally substituted  $C_3$ - $C_6$  membered cycloalkyl containing  $C_3$ - $C_8$ ;  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$  and  $R_7$  are independently hydrogen, halogen, hydroxy, nitro,  $C_1$ - $C_4$  lower ester,  $C_1$ - $C_4$  lower alkyl,  $C_1$ - $C_4$  lower alkoxy, aryl, arylalkoxy or unsaturated amine;  $l$  is an integer of 0-7;  $m$  and  $n$  are independently an integer of 0-1;  $W$  is carbon or nitrogen;  $X$  is oxygen, sulfur, optionally substituted imine;  $Y$  is nitrogen or oxygen; and  $Z$  is hydrogen,  $C_1$ - $C_8$  alkoxy, aryloxy,  $C_1$ - $C_4$  alkylamine, cycloamine containing  $N_1$ - $N_5$  or oxo group. The present compounds of the above formula (I) have not only strong antitumor activities but lower toxicities, and accordingly are expected as novel antitumor agents.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

- 1 -

# **New piperazine derivatives and methods for the preparation thereof and compositions containing the same**

The present invention relates to new piperazine derivatives of the general  
 5 formula(I)

10



( I )

wherein  $R_1$  and  $R_2$  are independently hydrogen,  $C_1$ - $C_8$  alkyl or optionally  
 15 substituted  $C_3$ - $C_6$  membered cycloalkyl containing  $C_3$ - $C_8$ ;  $R_3, R_4, R_5, R_6$  and  
 $R_7$  are independently hydrogen, halogen, hydroxy, nitro,  $C_1$ - $C_4$  lower ester,  
 $C_1$ - $C_4$  lower alkyl,  $C_1$ - $C_4$  lower alkoxy, aryl, arylalkoxy or unsaturated amine;  
 $l$  is an integer of 0-7;  $m$  and  $n$  are independently an integer of 0-1;  $W$  is  
 carbon or nitrogen;  $X$  is oxygen, sulfur, optionally substituted imine;  $Y$  is  
 20 nitrogen or oxygen; and  $Z$  is hydrogen,  $C_1$ - $C_8$  alkoxy, aryloxy,  $C_1$ - $C_4$   
 alkylamine, cycloamine containing  $N_1$ - $N_5$  or oxo group.

$C_1$ - $C_8$  alkyl means straight or branch alkyl group such as methyl, ethyl,  
 propyl, butyl, isobutyl, tert-butyl, pentyl, iso-pentyl, hexyl, heptyl, octyl,  
 25 2-methyl-pentyl or the like.

$C_1$ - $C_4$  lower alkyl means methyl, propyl, iso-propyl, n-butyl, iso-butyl,  
 tert-butyl or the like.

Optionally substituted 3-6 membered cycloalkyl containing  $C_3$ - $C_8$  means  
 substituted or unsubstituted cycloalkyl such as cyclopropyl, cyclobutyl,  
 30 cyclopentyl, cyclohexyl, substituted cyclopropyl, substituted cyclopentyl,  
 substituted cyclohexyl or the like.

$C_1$ - $C_4$  lower ester means a carboxyl group esterified by lower alkyl group.

$C_1$ - $C_4$  lower alkoxy means methoxy, ethoxy, propyloxy, isopropyloxy, butyloxy,  
 isobutyloxy, tert-butyloxy group or the like.


35 Aryloxy means phenoxy, substituted phenoxy, naphthyloxy or substituted  
 naphthyloxy or the like.

Cycloamine group containing  $N_1$ - $N_5$  means pyrrolidiny, pyrrolinyl, imidazolyl,

- 2 -

imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, tetrazolyl, piperazinyl or the like.

The general formula(I) compound wherein Z is oxo has the structural  
5 formula(I') by tautomerism.



( I ' )

The present inventors had studied to find compounds having intensive antitumor activity for a long time. As the results, we finally found out the  
15 facts that the foresaid compounds of the general formula(I) and acid addition salts thereof have not only prominent antitumor activity but very low toxicity. Accordingly, the one object of the present invention is to provide the novel compounds of the general formula(I) and acid addition salts thereof having not only prominent antitumor activity but very low toxicity.  
20 The other object of the present invention is to provide a process for the preparation of the compounds of general formula(I) and acid addition salts thereof.

The compounds of the present invention can be mixed with pharmaceutically acceptable vehicles by a known method to give pharmaceutical compositions  
25 and the pharmaceutical compositions can be used to prevent or treat various kinds of tumors of human beings or mammals.

Therefore, another object of the present invention is to provide pharmaceutical compositions containing the compounds of the general formula(I) and acid addition salts thereof as active ingredients.

30 Acids which can be reacted with the compounds of the general formula(I) to form acid addition salts are pharmaceutically acceptable inorganic or organic acids such as hydrochloric acid, bromic acid, sulfuric acid, phosphoric acid, nitric acid, formic acid, acetic acid, propionic acid, succinic acid, citric acid, maleic acid, malonic acid, glycolic acid, lactic acid, glycine, alanine, valine,  
35 leucine, isoleucine, serine, cysteine, cystine, asparaginic acid, glutamic acid, lysine, arginine, tyrosine, proline, methane sulfonic acid, ethane sulfonic acid, benzene sulfonic acid, toluene sulfonic acid or the like.


- 3 -

Vehicles which can be used in the preparation of pharmaceutical compositions containing the compounds of the general formula(I) as active ingredient are sweetening agent, binding agent, dissolving agent, aids for dissolution, wetting agent, emulsifying agent, isotonic agent, adsorbent, degrading agent, antioxidant, antiseptics, lubricating agent, filler and perfume or the like such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, sodium carboxy methyl cellulose, agar, talc, stearic acid, magnesium stearate, calcium stearate, magnesium aluminum silicate, starch, gelatine, tragacanth gum, methyl cellulose, glycine, silica, alginic acid, sodium alginate, water, ethanol, polyethylenglycol, polyvinyl pyrrolidone, sodium chloride, potassium chloride, orange essence, vanilla aroma or the like.

Daily dosage of the compound of the general formula(I) may be varied depending on age, sex of patient and the degree of disease. Daily dosage is 1.0mg to 5,000mg and may be administered one to several times.

The compounds of the general formula(I) may be prepared by the following scheme 1.

Scheme 1



- 4 -

wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $W$ ,  $X$ ,  $Y$ ,  $Z$ ,  $l$  and  $n$  are the same above and  $Lie_1$  is a leaving group like hydrogen.


The compounds of the general formula(I) may be prepared by reacting a compound of the general formula(a) in the presence of  $-CX-$  group-providing agent with a compound of the general formula(b).  $-CX-$  group-providing agent comprises 1,1-carbonyldiimidazole, 1,1-carbonylthiodiimidazole, phosgene, thiophosgene, carbonyldiphenoxide, chlorophenoxyformate or the like. The reaction may be carried out in conventional organic solvent such as tetrahydrofuran, dichloromethane, acetonitrile or the like. And also the reaction is preferably carried out in the presence of scavenger such as conventional inorganic or organic base.

The reaction may be carried out between  $3^\circ\text{C}$  and boiling point of the solvent used, preferably at  $50^\circ\text{C}$ - $100^\circ\text{C}$  for 5 - 48 hours, preferably for 10 - 24 hours.

Quantity of  $-CX-$  group-providing agent may be 1 - 1.5 equivalent, preferably 1-1.1 equivalent to the starting compound.

The compounds of the general formula(I) may be prepared by Scheme II.

### Scheme II



35 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $W$ ,  $X$ ,  $Y$ ,  $Z$ ,  $l$ ,  $n$ , and  $Lie_1$  are the same above and  $Lie_2$  is halogen.


The compound of the general formula(c) may be prepared by reacting a

- 5 -

compound of the general formula(a) in the presence of -CX-providing agent with piperazine in a solvent such as tetrahydrofuran, acetonitrile or the like under the same reaction condition of Scheme I. And then the compound of the general formula(I) may be prepared by reacting the compound of the general formula(c) in a solvent such as tetrahydrofuran or the like with a compound of the general formula (d) at 25 - 80 °C for 30 min - 20 hours.

The compounds of the general formula(I) may be prepared by Scheme III.

### 10 Scheme III




wherein, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, l, m, n, W, X, Y, Z and Lie<sub>1</sub> are the same above and Hal is halogen.

30 The compound of the general formula(f) may be prepared by reacting a compound of the general formula(a) with a compound of the general formula(e) and halogenating agent. And then the compound of the general formula(I) may be prepared by reacting the compound of the general formula(f) with a compound of the general formula(b).

35

The compound of the general formula(I') may be prepared by Scheme IV.


Scheme IV

15 wherein  $R_1$ ,  $R_2$ ,  $R_3$ ,  $R_4$ ,  $R_5$ ,  $R_6$ ,  $R_7$ ,  $l$ ,  $m$ ,  $n$ ,  $W$ ,  $X$ ,  $Y$ ,  $Z$ , and  $Lie_1$  are the same above.

The compound of the general formula(I') may be prepared by reacting a compound of the general formula(a') in the presence of CX-providing agent in a solvent like tetrahydrofuran or the like with a compound of the general formula (b) at ambient temperature for 30 min - 5 hours.

20

The compounds of the general formula(I) may be prepared by Scheme V.

Scheme V





- 7 -

wherein,  $R_1, R_2, R_3, R_4, R_5, R_6, R_7, l, m, n, W, X, Y, Z$  are the same above and  $R_8$  is  $C_1 - C_5$  alkyl or aryl group,  $Le$  is a leaving group like hydrogen. The compound of general formula(g) and the compound of general formula(h) may be prepared by condensing agent.

- 5 In the above reactions, if any acid material is formed, any basic material is preferably added as scavenger in order to eliminating the acid material from the reaction phase. Such basic material may be alkali metal hydroxide, alkali earth metal hydroxide, alkali metal oxide, alkali earth metal oxide, alkali metal carbonate, alkali earth metal carbonate, alkali metal hydrogen carbonate, alkali
- 10 earth metal hydrogen carbonate such as sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, calcium oxide, magnesium oxide, potassium carbonate, sodium carbonate, calcium carbonate, magnesium carbonate, magnesium bicarbonate, sodium bicarbonate, calcium bicarbonate or the like and organic amines.
- 15 The compound of the general formula(a) is described in prior art ( J. Med. Chem., 1992, 35, 3784, 3792 ) or may be prepared in a similar method to the art.

#### EXAMPLES:

- 20 The compounds of the general formula(I) and (I') are prepared by the following examples.



35

wherein  $R_1, R_2, R_3, R_4, R_5, R_6, R_7, l, m, n, W, X, Y, Z$  are the same above.

- 8 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
(l,m,n=integer)														
1	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	0	0	0
2	Me	Et	H	H	H	H	H	O	NH	OMe	C	0	0	0
3	Me	Et	H	H	OMe	H	H	O	NH	OMe	C	0	0	0
4	Me	Et	H	OMe	OMe	H	H	O	NH	OMe	C	0	0	0
5	Me	Et	OMe	H	OMe	H	H	O	NH	OMe	C	0	0	0
6	Me	Et	H	OMe	H	OMe	H	O	NH	OMe	C	0	0	0
7	Me	Et	H	OMe	OMe	OMe	H	O	NH	OMe	C	0	0	0
8	Me	Et	OEt	H	H	H	H	O	NH	OMe	C	0	0	0
9	Me	Et	OPh	H	H	H	H	O	NH	OMe	C	0	0	0
10	Me	Et	H	OPh	H	H	H	O	NH	OMe	C	0	0	0
11	Me	Et	F	H	H	H	H	O	NH	OMe	C	0	0	0
12	Me	Et	H	H	F	H	H	O	NH	OMe	C	0	0	0
13	Me	Et	H	F	H	F	H	O	NH	OMe	C	0	0	0
14	Me	Et	H	CF <sub>3</sub>	H	H	H	O	NH	OMe	C	0	0	0
15	Me	Et	Cl	H	H	H	H	O	NH	OMe	C	0	0	0

- 9 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
(l, m, n = integer)														
16	Me	Et	H	Cl	H	H	H	O	NH	OMe	C	0	0	0
17	Me	Et	Cl	H	H	H	Cl	O	NH	OMe	C	0	0	0
18	Me	Et	H	Cl	H	Cl	H	O	NH	OMe	C	0	0	0
19	Me	Et	Cl	H	Cl	H	H	O	NH	OMe	C	0	0	0
20	Me	Et	Cl	H	Cl	H	Cl	O	NH	OMe	C	0	0	0
21	Me	Et	Br	H	H	H	H	O	NH	OMe	C	0	0	0
22	Me	Et	H	Br	H	H	H	O	NH	OMe	C	0	0	0
23	Me	Et	H	H	Br	H	H	O	NH	OMe	C	0	0	0
24	Me	Et	Br	H	Br	H	H	O	NH	OMe	C	0	0	0
25	Me	Et	Br	H	H	Br	H	O	NH	OMe	C	0	0	0
26	Me	Et	Me	H	H	H	H	O	NH	OMe	C	0	0	0
27	Me	Et	H	H	Me	H	H	O	NH	OMe	C	0	0	0
28	Me	Et	Me	Me	H	H	H	O	NH	OMe	C	0	0	0
29	Me	Et	H	Me	H	Me	H	O	NH	OMe	C	0	0	0
30	Me	Et	Me	H	H	H	Me	O	NH	OMe	C	0	0	0

- 10 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
(l,m,n=integer)														
31	Me	Et	H	H	i-Pr	H	H	O	NH	OMe	C	0	0	0
32	Me	Et	i-Pr	H	H	H	H	O	NH	OMe	C	0	0	0
33	Me	Et	H	H	n-Bu	H	H	O	NH	OMe	C	0	0	0
34	Me	Et	H	H	Ac	H	H	O	NH	OMe	C	0	0	0
35	Me	Et	Ph	H	H	H	H	O	NH	OMe	C	0	0	0
36	Me	Et	H	H	Ph	H	H	O	NH	OMe	C	0	0	0
37	Me	Et	OH	H	H	H	H	O	NH	OMe	C	0	0	0
38	Me	Et	H	OH	H	H	H	O	NH	OMe	C	0	0	0
39	Me	Et	H	H	OH	H	H	O	NH	OMe	C	0	0	0
40	Me	Et	H	H	OAc	H	H	O	NH	OMe	C	0	0	0
41	Me	Et	H	OAc	H	H	H	O	NH	OMe	C	0	0	0
42	Me	Et	H	H	NO <sub>2</sub>	H	H	O	NH	OMe	C	0	0	0
43	Me	Et	NHCH <sub>3</sub>	H	H	H	H	O	NH	OMe	C	0	0	0
44	Me	Et	H	H	H	-benzo-		O	NH	OMe	C	0	0	0
45	Me	Et	H	H	H	-naphtho-		O	NH	OMe	C	0	0	0

- 11 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
(l, m, n = integer)														
46	Me	Et	OMe	H	H	H	Me	O	NH	OMe	C	0	0	0
47	Me	Et	OMe	H	H	Me	H	O	NH	OMe	C	0	0	0
48	Me	Et	Me	H	H	OMe	H	O	NH	OMe	C	0	0	0
49	Me	Et	OMe	H	H	Cl	H	O	NH	OMe	C	0	0	0
50	Me	Et	Cl	H	H	OMe	H	O	NH	OMe	C	0	0	0
51	Me	Et	H	Cl	OMe	H	H	O	NH	OMe	C	0	0	0
52	Me	Et	H	OH	OMe	H	H	O	NH	OMe	C	0	0	0
53	Me	Et	H	OAc	OMe	H	H	O	NH	OMe	C	0	0	0
54	Me	Et	OMe	H	H	Ph	H	O	NH	OMe	C	0	0	0
55	Me	Et	Me	OH	H	H	H	O	NH	OMe	C	0	0	0
56	Me	Et	OH	H	H	H	Me	O	NH	OMe	C	0	0	0
57	Me	Et	OH	H	Me	H	H	O	NH	OMe	C	0	0	0
58	Me	Et	Me	H	H	Cl	H	O	NH	OMe	C	0	0	0
59	Me	Et	H	Cl	F	H	H	O	NH	OMe	C	0	0	0
60	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	1	0	0

- 12 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
(l, m, n = integer)														
61	Me	Et	F	H	H	H	H	O	NH	OMe	C	1	0	0
62	Me	Et	H	H	F	H	H	O	NH	OMe	C	1	0	0
63	Me	Et	H	Cl	H	H	H	O	NH	OMe	C	1	0	0
64	Me	Et	H	H	F	H	H	O	NH	OMe	C	2	0	0
65	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	2	0	0
66	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	3	0	0
67	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	5	0	0
68	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	7	0	0
69	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	0	1	0
70	Me	Et	H	Cl	H	H	H	O	NH	OMe	C	0	1	0
71	Me	Et	F	H	H	H	H	O	NH	OMe	C	0	1	0
72	Me	Et	H	H	H	H	H	O	NH	OMe	C	0	0	1
73	Me	Et	H	H	OMe	H	H	O	NH	OMe	C	0	0	1
74	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	0	0	1
75	Me	Et	H	H	F	H	H	O	NH	OMe	C	0	0	1

- 13 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	I	m	n
(1, m, n = integer)														
76	Me	Et	OMe	H	H	H	H	O	NH	OEt	C	0	0	0
77	Me	Et	F	H	H	H	H	O	NH	OEt	C	0	0	0
78	Me	Et	H	Cl	H	H	H	O	NH	OEt	C	0	0	0
79	Me	Et	OEt	H	H	H	H	O	NH	OEt	C	0	0	0
80	Me	Et	OMe	H	H	H	H	O	NH	OPh	C	0	0	0
81	Me	Et	H	Cl	H	H	H	O	NH	OPh	C	0	0	0
82	Me	Et	H	OAc	H	H	H	O	NH	OPh	C	0	0	0
83	Me	Et	F	H	H	H	H	O	NH	OPh	C	0	0	0
84	Me	Et	H	Me	H	Me	H	O	NH	OPh	C	0	0	0
85	Me	Et	H	OMe	H	OMe	H	O	NH	OPh	C	0	0	0
86	Me	Et	H	Cl	H	Cl	H	O	NH	OPh	C	0	0	0
87	Me	Et	H	OH	OMe	H	H	O	NH	OPh	C	0	0	0
88	Me	Et	H	OH	H	H	H	O	NH	OPh	C	0	0	0
89	Me	Et	OMe	H	H	H	H	O	NH	NHCH <sub>3</sub>	C	0	0	0
90	Me	Et	H	OMe	H	OMe	H	O	NH	NHCH <sub>3</sub>	C	0	0	0

- 14 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
(l, m, n = integer)														
91	Me	Et	H	Cl	H	H	H	O	NH	NHCH <sub>3</sub>	C	0	0	0
92	Me	Et	OMe	H	H	H	H	O	NH	H	C	0	0	0
93	Me	Et	H	OMe	H	OMe	H	O	NH	H	C	0	0	0
94	Me	Et	H	Cl	H	H	H	O	NH	piperazine	C	0	0	0
95	Me	Et	H	Cl	H	H	H	O	NH	piperazine	C	0	0	0
96	Me	Et	OMe	H	H	H	H	O	NH	piperazine	C	0	0	0
97	Me	Et	OMe	H	H	H	H	S	NH	OMe	C	0	0	0
98	Me	Et	H	Cl	H	H	H	S	NH	OMe	C	0	0	0
99	Me	Et	F	H	H	H	H	S	NH	OMe	C	0	0	0
100	Me	Et	H	OMe	H	OMe	H	S	NH	OMe	C	0	0	0
101	Me	Et	H	Cl	H	Cl	H	S	NH	OMe	C	0	0	0
102	Me	Et	OMe	H	H	H	H	O	O	OMe	C	0	0	0
103	Me	Et	H	Cl	H	H	H	O	O	OMe	C	0	0	0
104	Me	Et	H	OMe	H	OMe	H	O	O	OMe	C	0	0	0
105	Me	Et	OMe	H	H	H	H	O	O	OMe	C	1	0	0



- 15 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
(l,m,n=integer)														
106	Me	Et	H	Cl	H	H	H	O	O	OMe	C	1	0	0
107	Me	Me	H	H	H	H	H	O	NH	OMe	C	0	0	0
108	Me	Me	OMe	H	H	H	H	O	NH	OMe	C	0	0	0
109	Me	Me	H	Cl	H	H	H	O	NH	OMe	C	0	0	0
110	Me	Me	F	H	H	H	H	O	NH	OMe	C	0	0	0
111	Me	Me	H	F	H	F	H	O	NH	OMe	C	0	0	0
112	Me	Me	OH	H	H	H	H	O	NH	OMe	C	0	0	0
113	Me	Me	H	OH	H	H	H	O	NH	OMe	C	0	0	0
114	Me	Me	H	H	OH	H	H	O	NH	OMe	C	0	0	0
115	Me	Me	H	OAc	H	H	H	O	NH	OMe	C	0	0	0
116	Me	Me	H	H	OAc	H	H	O	NH	OMe	C	0	0	0
117	Me	Me	H	OAc	OMe	H	H	O	NH	OMe	C	0	0	0
118	Me	Me	H	OMe	H	OMe	H	O	NH	OMe	C	0	0	0
119	Me	Me	Me	Me	H	H	H	O	NH	OMe	C	0	0	0
120	Me	Me	H	Me	H	Me	H	O	NH	OMe	C	0	0	0

- 16 -

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
(l,m,n=integer)														
121	Me	Me	Me	H	H	OMe	H	O	NH	OMe	C	0	0	0
122	Me	Me	OH	H	Me	H	H	O	NH	OMe	C	0	0	0
123	Me	Me	H	OH	OMe	H	H	O	NH	OMe	C	0	0	0
124	Me	Me	H	H	H	-benzo-		O	NH	OMe	C	0	0	0
125	Me	Me	H	H	H	-naphtho-		O	NH	OMe	C	0	0	0
126	Me	Me	H	Cl	H	H	H	S	NH	OMe	C	0	0	0
127	Me	Me	H	Cl	H	Cl	H	S	NH	OMe	C	0	0	0
128	Me	Me	OMe	H	H	H	H	S	NH	OMe	C	0	0	0
129	Me	Me	H	OMe	H	OMe	H	S	NH	OMe	C	0	0	0
130	-(CH <sub>2</sub> ) <sub>3</sub> -		OMe	H	H	H	H	O	NH	OMe	C	0	0	0
131	-(CH <sub>2</sub> ) <sub>3</sub> -		H	Cl	H	H	H	O	NH	OMe	C	0	0	0
132	-(CH <sub>2</sub> ) <sub>3</sub> -		F	H	H	H	H	O	NH	OMe	C	0	0	0
133	-(CH <sub>2</sub> ) <sub>4</sub> -		OMe	H	H	H	H	O	NH	OMe	C	0	0	0
134	-(CH <sub>2</sub> ) <sub>4</sub> -		H	Cl	H	H	H	O	NH	OMe	C	0	0	0
135	-(CH <sub>2</sub> ) <sub>4</sub> -		F	H	H	H	H	O	NH	OMe	C	0	0	0

ex. no	R <sup>1</sup>	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>6</sup>	R <sup>7</sup>	X	Y	Z	W	l	m	n
												(l,m,n=integer)		
136	Me	i-Pr	OMe	H	H	H	H	O	NH	OMe	C	0	0	0
137	Me	i-Pr	H	Cl	H	H	H	O	NH	OMe	C	0	0	0
138	Me	i-Pr	F	H	H	H	H	O	NH	OMe	C	0	0	0
139	H	H	H	H	H	H	H	O	NH	OMe	C	0	0	0
140	H	H	OMe	H	H	H	H	O	NH	OMe	C	0	0	0
141	H	H	H	H	OMe	H	H	O	NH	OMe	C	0	0	0
142	H	H	H	Cl	H	H	H	O	NH	OMe	C	0	0	0
143	Me	Et	NHCH <sub>2</sub> COH	H	H	H	H	O	NH	OMe	N	0	0	0
144	Me	Et	NHCH <sub>2</sub> COH	H	H	H	H	O	NH	OMe	N	1	0	0
145	Me	Et	NHCH <sub>2</sub> COH	H	H	H	H	O	NH	=O	N	1	0	0
146	Me	Et	N(CH <sub>2</sub> Ph) <sub>2</sub>	H	H	H	H	O	NH	=O	N	1	0	0
147	Me	i-Pr	NHEt	H	H	H	H	O	NH	=O	N	1	0	0
148	Me	Et	OMe	H	H	H	H	O	NH	OMe	C	0	0	0
149	Me	Et	H	Cl	H	H	H	O	NH	OMe	C	0	0	0

- 18 -

## Example 1

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate(0.29g, 1.0mmol)  
 5 and 1-(2-methoxyphenyl)piperazine(0.19g, 1.0mmol) were dissolved in tetrahydrofuran(10ml) and DBU(0.15g, 1.0mol) was added thereto and the mixture was stirred at room temperature for 2 hours. Then, the reaction mixture was concentrated and chromatographed to obtain 0.33g of the titled compound.

10 yield: 89 %

<sup>1</sup>H-NMR(500MHZ, CDCl<sub>3</sub>): δ 1.17(3H,t,J=7.5Hz), 2.37(3H,s), 2.55(2H,q,J=7.5Hz),  
 3.11(4H,t,J=4.6Hz), 3.69(4H,t,J=5.0Hz), 3.88(1H,s),  
 3.98(3H,s), 6.89(1H,s), 6.94(3H,m), 7.05(1H,m),  
 8.21(1H,s).

15 Elemental Analysis: C<sub>21</sub>H<sub>28</sub>N<sub>4</sub>O<sub>3</sub>: Calc., C,65.60, H,7.34, N,14.57.

Found, C,66.10, H,7.25, N,14.57.

## Example 2

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4 phenylpiperazine:  
 20 ne:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
 1-phenylpiperazine were reacted by the same way with the example 1 to  
 obtain the titled compound.

yield: 86 %

25

## Example 3

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
 30 1-(4-methoxyphenyl)piperazine were reacted by the same way with the  
 example 1 to obtain the titled compound.

yield: 78 %

## Example 4

35 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,4-dimethoxyphenyl)piperazine:

Phenyl N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and

1-(3,4-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:69 %

## 5 Example 5

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,4-dimethoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2,4-dimethoxyphenyl)piperazine were reacted by the same way with the

10 example 1 to obtain the titled compound.

yield: 77 %

### Example 6

15, -1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield : 82 %

### Example 7

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,4,5-trimethoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
25 1-(3,4,5-trimethoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

yield : 52 %

### Example 8

30 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-ethoxyphen-  
yl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2-ethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

35 yield : 78 %

### Example 9

- 20 -

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-phenoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-phenoxyphenyl)piperazine were reacted by the same way with the  
5 example 1 to obtain the titled compound.  
yield : 69 %

#### Example 10

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-phenoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3-phenoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield : 72 %

15

#### Example 11

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
20 1-(2-fluorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield : 67 %

#### Example 12

25 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-fluorophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(4-fluorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.

30 yield : 81 %

#### Example 13

1-[(5-ethyl-2-methoxy-6-methylpyridine-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl)piperazine:

35 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3,5-difluorophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

- 21 -

yield : 69 %

Example 14

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-( $\alpha, \alpha, \alpha$ -trifluoro-m-tolyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-( $\alpha, \alpha, \alpha$ -trifluoro-m-tolyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield: 67 %

10

Example 15

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-chlorophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2-chlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :82 %

Example 16

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3-chlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

25 yield :84 %

Example 17

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,6-dichlorophenyl)piperazine:

30 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2,6-dichlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :80 %

35 Example 18

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)piperazine:

- 22 -

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield :69 %

5

## Example 19

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,4-dichlorophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
10 1-(2,4-dichlorophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield :72 %

## Example 20

15 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,4,6-trichlorophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2,4,6-trichlorophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
20 yield :54 %

## Example 21

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-bromophenyl)piperazine:

25 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-bromophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield :58 %

## 30 Example 22

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-bromophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3-bromophenyl)piperazine were reacted by the same way with the example  
35 1 to obtain the titled compound.  
yield :65 %



- 23 -

## Example 23

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-bromophen-yl)piperazine:

- Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
5 1-(4-bromophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.  
yield :64 %

## Example 24

- 10 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,4-dibromophenyl)piperazine:

- Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2,4-dibromophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
15, yield :68 %

## Example 25

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,5-dibromophenyl)piperazine:

- 20 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2,5-dibromophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield :66 %

## 25 Example 26

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-tolyl)piperazine:

- Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-tolyl)piperazine were reacted by the same way with the example 1 to  
30 obtain the titled compound.  
yield :89 %

## Example 27

- 35 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-methylphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(4-methylphenyl)piperazine were reacted by the same way with the example

- 24 -

1 to obtain the titled compound.

yield :87 %

Example 28

5 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,3-dimethylphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2,3-dimethylphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

10 yield :82 %

Example 29

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethylphenyl)piperazine:

15 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3,5-dimethylphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

yield :68 %

20 Example 30

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2,6-dimethylphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2,6-dimethylphenyl)piperazine were reacted by the same way with the

25 example 1 to obtain the titled compound

yield :80 %

Example 31

30 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-isopropylphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(4-isopropylphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

yield :68 %

35

Example 32

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-isopropylph-

enyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-isopropylphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

5 yield :65 %

Example 33

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-normalbutyl-  
phenyl)piperazine:

10 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(4-normalbutylphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

yield :57 %

15 Example 34

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-acetylphen-  
yl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(4-acetylphenyl)piperazine were reacted by the same way with the example

20 1 to obtain the titled compound.

yield :67 %

Example 35

25 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-biphenyl)pi-  
perazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-biphenyl)piperazine were reacted by the same way with the example 1 to  
obtain the titled compound.

yield :82 %

30

Example 36

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-biphenyl)pi-  
perazine:

35 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(4-biphenyl)piperazine were reacted by the same way with the example 1 to  
obtain the titled compound.

yield :81 %

## Example 37

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-hydroxyphenyl)piperazine:

- 5 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-hydroxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield :59 %

## 10 Example 38

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-hydroxyphenyl)piperazine:

- Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3-hydroxyphenyl)piperazine were reacted by the same way with the  
15 example 1 to obtain the titled compound.  
yield :63 %

## Example 39

20 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-hydroxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(4-hydroxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield :58 %

25

## Example 40

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-acetoxyphe-  
nyl)piperazine:

- Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
30 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield :89 %

## Example 41

35 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-acetoxyphe-  
nyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and

- 27 -

1-(3-acetoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :87 %

5 Example 42

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-nitrophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(4-nitrophenyl)piperazine were reacted by the same way with the example 1

10 to obtain the titled compound.

yield :70 %

Example 43

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-[(2-methylamino)phenyl]piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-[2-(methylamino)phenyl]piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :59 %

20

Example 44

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(1-naphthyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(1-naphthyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :63 %

Example 45

30 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(1-anthryl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(1-anthryl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

35 yield :57 %

Example 46

- 28 -

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxy-6-methylphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-methoxy-6-methylphenyl)piperazine were reacted by the same way with  
5 the example 1 to obtain the titled compound.  
yield :67 %

Example 47

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxy-5-  
10 methylphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-methoxy-5-phenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield :62 %

15

Example 48

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(5-methoxy-2-  
methylphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
20 1-(5-methoxy-2-methylphenyl)piperazine were reacted by the same way with  
the example 1 to obtain the titled compound.  
yield :66 %

Example 49

25 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(5-chloro-2-  
methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(5-chloro-2-methoxyphenyl)piperazine were reacted by the same way with  
the example 1 to obtain the titled compound.  
30 yield :69 %

Example 50

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-chloro-5-  
methoxyphenyl)piperazine:

35 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-chloro-5-methoxyphenyl)piperazine were reacted by the same way with  
the example 1 to obtain the titled compound.

- 29 -

yield :70 %

Example 51

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-chloro-4-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3-chloro-4-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :62 %

10

Example 52

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-hydroxy-4-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3-hydroxy-4-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :59 %

Example 53

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-acetoxy-4-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(3-acetoxy-4-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

25 yield :62 %

Example 54

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-[(2-methoxy-5-phenyl)phenyl]piperazine:

30 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-[(2-methoxy-5-phenyl)phenyl]piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :67 %

35 Example 55

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-hydroxy-2-methylphenyl)piperazine:

- 30 -

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3-hydroxy-2-methylphenyl)piperazine were reacted by the same way with  
the example 1 to obtain the titled compound.  
5 yield :54 %

Example 56

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-hydroxy-6-  
methylphenyl)piperazine:  
10 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-hydroxy-6-methylphenyl)piperazine were reacted by the same way with  
the example 1 to obtain the titled compound.  
yield :57 %

15 Example 57

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-hydroxy-4-  
methylphenyl)piperazine:  
Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
20 1-(2-hydroxy-4-methylphenyl)piperazine were reacted by the same way with  
example 1 to obtain the titled compound.  
yield :52 %

Example 58

25 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(5-chloro-2-  
methylphenyl)piperazine:  
Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(5-chloro-2-methylphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
30 yield :63 %

Example 59

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-chloro-4-  
fluorophenyl)piperazine:  
35 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3-fluorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield :65 %



## Example 60

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

- 5 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-methoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield :69 %

## 10 Example 61

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-chlorophenyl)piperazine:

- Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-chlorophenyl)piperazine were reacted by the same way with the example  
15 1 to obtain the titled compound.  
yield :72 %

## Example 62

- 20 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)methylaminocarbonyl]-4-(4-fluorophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(4-fluorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield :63 %

25

## Example 63

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)methylaminocarbonyl]-4-(3-chlorophenyl)piperazine:

- 30 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield :68 %

## Example 64

- 35 1-[[5-ethyl-2-methoxy-6-methylpyridin-3-yl]ethylaminocarbonyl]-4-(4-fluorophenyl)piperazine:

Phenyl-N-[2-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)ethyl]carbamate and  
1-(4-fluorophenyl)piperazine were reacted by the same way with the example

- 32 -

1 to obtain the titled compound.

yield :65 %

#### Example 65

5 1-([2-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)ethyl]aminocarbonyl)-4-(2-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

10 yield :63 %

#### Example 66

1-([3-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)propyl]aminocarbonyl)-4-(2-methoxyphenyl)piperazine:

15 Phenyl-N-[3-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)propyl]carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :67 %

#### 20 Example 67

1-([5-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)pentyl]aminocarbonyl)-4-(2-methoxyphenyl)piperazine:

Phenyl-N-[5-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)pentyl]carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

25 yield :52 %

#### Example 68

1-([6-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)heptyl]aminocarbonyl)-4-(2-methoxyphenyl)piperazine:

Phenyl-N-[6-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)heptyl]carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield :49 %

35

#### Example 69

1-([5-ethyl-2-methoxy-6-methylpyridin-3-yl]aminocarbonyl)methyl-4-(2-met-

hoxypyphenyl)piperazine:

a) N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)chloroacetamide:

After chloroacetic acid (1.35 g, 14.3 mmol) were dissolved into 20 ml of tetrahydrofuran, added 1,1-carbonyldiimidazole(2.32g, 14.3mmol), stirred at  
 5 room temperature for 1 hour, 3-amino-5-ethyl-2-methoxy-6-methylpyridine (2.0g, 13.0mmol) were added. After the reaction mixture were stirred for 2 hours, the mixture of reaction were concentrated, purified by column chromatography to obtain 2.20g of the titled compound.  
 yield:73.3%

10 <sup>1</sup>H-NMR(500MHz, CDCl<sub>3</sub>); δ 1.17(3H,t), 2.39(5H,m), 3.99(3H,s), 4.17(2H,s),  
 8.62(1H,s)

b) 1-[(5-ethyl-2-methoxy-6-methylpyridine-3-yl)aminocarbonyl]methyl-4-(2-methoxyphenyl)piperazine:

After N-(5-ethyl-2-methoxy-6-methylpyridine-3-yl)chloroacetamide(0.10g,  
 15 0.43mmol) and 1-(2-methoxyphenyl)piperazine(0.0091g, 0.47mmol) were dissolved into tetrahydrofuran(5ml) and was added DBU(0.060g, 0.43mmol), the reaction mixtures were stirred at room temperature for 2 hours. After the product of reaction were concentrated, separated by column chromatography to obtain 0.12g of the titled compound.  
 20 yield:70%

Example 70.

1-[(5-ethyl-2-methoxy-6-methylpyridine-3-yl)aminocarbonyl]methyl-4-(3-chlorophenyl)piperazine:

25 N-(5-ethyl-2-methoxy-6-methylpyridine-3-yl)chloroacetamide and 1-(3-chlorophenyl)piperazine were reacted by the same way with the example 69 to obtain the titled compound.  
 yield:68%

30 Example 71.

1-[(5-ethyl-2-methoxy-6-methylpyridine-3-yl)aminocarbonyl]methyl-4-(2-fluorophenyl)piperazine:

N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)chloroacetamide and 1-(3-fluorophenyl)piperazine were reacted by the same way with the example  
 35 69 to obtain the titled compound.  
 yield:68%

## Example 72.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-benzylpiperazine:

5 a) 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-methoxybenzyl)piperazine.

After 3-amino-5-ethyl-2-methoxy-6-methylpyridine(1.06g, 6.35mmol) was dissolved in 20ml of tetrahydrofuran, 1,1'-carbonyldiimidazole(1.08g, 6.67mmol) was added thereto. The mixture of reaction was stirred at room temperature for half hour and then benzylpiperazine(1.12g, 6.35mmol) was added. After the reaction mixture was stirred for 2 hours, the reaction mixture was concentrated and chromatographed to obtain 1.78g of the oil phase of the titled compound.

yield:76%

15 <sup>1</sup>H-NMR(500MHz,CDCl<sub>3</sub>): δ 1.16(3H,t), 2.36(3H,s), 2.48(4H,t), 3.42(4H,s), 3.54(2H,t), 3.95(H,s), 7.31(5H,s), 8.19(1H,s)

b) 1-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl piperazine:

After 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-benzyl piperazine (1.71g, 4.61mmol) was added the solution of 30ml of ethanol and 10ml of glacial acetic acid in the presence of 5% Pd/C, the reaction mixture were stirred under hydrogen gas(40 psi) for 4 hours and extracted with dichloromethane. The mixture was dried with anhydrous magnesium sulfate, filtrated, concentrated and chromatographed to obtain 1.2 g of white solid of the titled compound.

yield:93%

25 <sup>1</sup>H-NMR(500MHz, CDCl<sub>3</sub>) : δ 1.16(3H,s), 2.35(3H,s), 2.48(2H,q), 2.94(4H,t), 3.52(4H,t), 8.02(1H,s)

c) 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-benzylpiperazine:

After 1-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl piperazine (0.16g, 0.57mmol) and benzylchloride(0.076g, 0.60mmol) were added in DMF 5ml in the presence of NaHCO<sub>3</sub>(0.114g, 1.36mmol), the reaction mixtures were stirred in 90°C for 4 hours. The reaction solution was cooled at room temperature and the reaction mixture was extracted with dichloromethane and chromatographed to obtain 0.082gm of the titled compound.

35 yield:39%

<sup>1</sup>H-NMR(500MHz, CDCl<sub>3</sub>): δ 1.16(3H,t), 2.36(3H,s), 2.48(4H,t), 3.42(4H,t), 3.54(2H,s), 3.95(5H,s), 7.31(5H,s), 8.19(1H,s)

- 35 -

## Example 73.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-methoxybenzyl)piperazine:

- 5 1-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonylpiperazine and 4-methoxybenzylchloride were reacted by the same way with the example 72 to obtain the titled compound.  
yield:42%

## 10 Example 74.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxybenzyl)piperazine:

- 1-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonylpiperazine and 2-methoxybenzylchloride were reacted by the same way with the example 72  
15 to obtain the titled compound.  
yield:47%

## Example 75.

- 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(4-fluorobenzyl)piperazine:

1-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonylpiperazine and 4-fluorobenzylchloride were reacted by the same way with the example 72 to obtain the titled compound.  
yield:52%

25

## Example 76.

1-[(2-ethoxy-5-ethyl-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

- Phenyl-N-(2-ethoxy-5-ethyl-6-methylpyridin-3-yl)carbamate and  
30 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.  
yield:82%

## Example 77.

- 35 1-[(2-ethoxy-5-ethyl-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine:

Phenyl-N-(2-ethoxy-5-ethyl-6-methylpyridin-3-yl)carbamate and

- 36 -

1-(2-fluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:87%

5 Example 78.

1-[(2-ethoxy-5-ethyl-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl) piperazine:

Phenyl-N-(2-ethoxy-5-ethyl-6-methylpyridin-3-yl)carbamate and

10 1-(3-chlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:83%

Example 79.

15 1-[(2-ethoxy-5-ethyl-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-ethoxyphenyl) piperazin:

Phenyl-N-(2-ethoxy-5-ethyl-6-methylpyridin-3-yl)carbamate and

1-(2-ethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:79%

20

Example 80.

1-[(5-ethyl-6-methyl-2-phenoxy pyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-6-methyl-2-phenoxy pyridin-3-yl)carbamate and

25 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:88%

Example 81.

30 1-[(5-ethyl-6-methyl-2-phenoxy pyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine:

Phenyl-N-(5-ethyl-6-methyl-2-phenoxy pyridin-3-yl)carbamate and

1-(3-chlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

35 yield:85%

Example 82.

- 37 -

1-[(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)aminocarbonyl]-4-(3-acetoxyphe-  
nyl)piperazine:

Phenyl-N-(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)carbamate and  
1-(3-acetoxyphe-  
nyl)piperazine were reacted by the same way with the  
5 example 1 to obtain the titled compound.  
yield:83%

Example 83.

1-[(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)aminocarbonyl]-4-(2-fluorophen-  
10 yl)piperazine:

Phenyl-N-(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)carbamate and  
1-(2-fluorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield:72%

15,

Example 84.

1-[(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)aminocarbonyl]-4-(3,5-xylyl)pip-  
erazine:

Phenyl-N-(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)carbamate and  
20 1-(3,5-xylyl)piperazine were reacted by the same way with the example 1 to  
obtain the titled compound.  
yield:78%

Example 85.

25 1-[(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)aminocarbonyl]-4-(3,5-dimethox-  
yphenyl)piperazine:

Phenyl-N-(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)carbamate and  
1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

30 yield:75%

Example 86.

1-[(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)aminocarbonyl]-4-(3,5-dichlorop-  
henyl)piperazine:

35 Phenyl-N-(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)carbamate and  
1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.

yield:82%

Example 87.

1-[(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)aminocarbonyl]-4-(3-hydroxy-4-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)carbamate and 1-(3-hydroxy-4-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:69%

10

Example 88.

1-[(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)aminocarbonyl]-4-(3-hydroxyphenyl)piperazine:

Phenyl-N-(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)carbamate and 1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:72%

Example 89.

20 1-[(5-ethyl-6-methyl-2-methylaminopyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-6-methyl-2-methylaminopyridin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

25 yield:73%

Example 90.

1-[(5-ethyl-6-methyl-2-methylaminopyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

30 Phenyl-N-(5-ethyl-6-methyl-2-methylaminopyridin-3-yl)carbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:82%

35 Example 91.

1-[(5-ethyl-6-methyl-2-phenoxy-pyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine:



- 39 -

Phenyl-N-(5-ethyl-6-methyl-2-methylaminopyridin-3-yl)carbamate and  
1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield:79%

5

Example 92.

1-[(5-ethyl-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperaz-  
ine:

Phenyl-N-(5-ethyl-6-methylpyridin-3-yl)carbamate and  
10 1-(2-methoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:80%

Example 93.

15 1-[(5-ethyl-6-methylpyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphenyl)pip-  
erazine:

Phenyl-N-(5-ethyl-6-methylpyridin-3-yl)carbamate and  
1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
20 yield:85%

Example 94.

1-([5-ethyl-6-methyl-2-(1-piperazinyl)pyridin-3-yl]aminocarbonyl)-4-(3-chlo-  
rophenyl)piperazine:

25 Phenyl-N-([5-ethyl-6-methyl-2-(1-piperazinyl)pyridin-3-yl]carbamate and  
4-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield:87%

30 Example 95.

1-([5-ethyl-6-methyl-2-(4-bocpiperazinyl)pyridin-3-yl]aminocarbonyl)-4-(3-  
chlorophenyl)piperazine:

Phenyl-N-([5-ethyl-6-methyl-2-(4-boc-piperazinyl)pyridin-3-yl]carbamate and  
1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
35 1 to obtain the titled compound.  
yield:92%

- 40 -

## Example 96.

1-([5-ethyl-6-methyl-2-(4-boc-piperazinyl)pyridin-3-yl]aminocarbonyl)-4-(2-methoxyphenyl)piperazine:

- 5 Phenyl-N-([5-ethyl-6-methyl-2-(4-boc-piperazinyl)pyridin-3-yl]carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.  
yield:94%

## Example 97.

- 10 1-([5-ethyl-2-methoxy-6-methylpyridin-3-yl]aminothiocarbonyl)-4-(2-methoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)thiocarbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

- 15 yield:93%

## Example 98.

1-([5-ethyl-2-methoxy-6-methylpyridin-3-yl]aminothiocarbonyl)-4-(3-chlorophenyl)piperazine:

- 20 Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)thiocarbamate and 1-(3-chlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.  
yield:88%

## 25 Example 99.

1-([5-ethyl-2-methoxy-6-methylpyridin-3-yl]aminothiocarbonyl)-4-(2-fluorophenyl)piperazine:

- Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)thiocarbamate and 1-(2-fluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.  
30 yield:82%

## Example 100.

- 35 1-([5-ethyl-2-methoxy-6-methylpyridin-3-yl]aminothiocarbonyl)-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridine-3-yl)thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the

- 41 -

example 1 to obtain the titled compound.

yield:85%

5

Example 101

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminothiocarbonyl]-4-(3,5-dichlorophenyl)piperazine:

Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)thiocarbamate and  
1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:84%

Example 102.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)oxycarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbonate and  
1-(2-methoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:72%

Example 103.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)oxycarbonyl]-4-(3-chlorophenyl)piperazine:

Phenyl-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbonate and  
1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield:74%

Example 104.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)oxycarbonyl]-4-(3,5-dimethoxyphenyl)piperazine:

Phenyl-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbonate and  
1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:77%

Example 105.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)methyloxycarbonyl]-4-(2-metho-

- 42 -

xyphenyl)piperazine:

Phenyl-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)methylcarbonate and  
1-(2-methoxyphenyl)piperazine were reacted by the same way with the  
5 example 1 to obtain the titled compound.  
yield:82%

Example 106.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)methyloxycarbonyl]-4-(3-chlorop  
10 henyl)piperazine:  
Phenyl-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)methylcarbonate and  
1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield:79%

15

Example 107.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-phenylpiperazine:  
Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-phenylpiperazine were reacted by the same way with the example 1 to  
20 obtain the titled compound.  
yield:84%

Example 108.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)  
25 piperazine:  
Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-(2-methoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:88%

30

Example 109.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)pi-  
perazine:  
Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
35 1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield:92%

- 43 -

## Example 110.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine:

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and

5 1-(2-fluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:79%

## Example 111.

10 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-difluorophenyl) piperazine:

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and

1-(3,5-difluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

15 yield:87%

## Example 112.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(2-hydroxyphenyl)piperazine:

20 Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and

1-(2-hydroxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:85%

## 25 Example 113.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3-hydroxyphenyl) piperazine:

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and

1-(3-hydroxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

30 yield:78%

## Example 114.

35 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(4-hydroxyphenyl) piperazine:

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and

1-(4-hydroxyphenyl)piperazine were reacted by the same way with the

- 44 -

example 1 to obtain the titled compound.  
yield:72%

Example 115.

- 5 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3-acetoxyphenyl)  
piperazine:  
Phenyl N (5,6 dimethyl 2 methoxypyridin 3 yl)carbamate and  
1-(3-acetoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
10 yield:92%

Example 116.

- 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(4-acetoxyphenyl)  
piperazine:  
15 Phenyl N (5,6 dimethyl 2 methoxypyridin 3 yl)carbamate and  
1-(4-acetoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:89%

20 Example 117.

- 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3-acetoxy-4-met-  
hoxyphenyl)piperazine:  
Phenyl N (5,6 dimethyl 2 methoxypyridine 3 yl)carbamate and  
1-(3-acetoxy-4-methoxyphenyl)piperazine were reacted by the same way  
25 with the example 1 to obtain the titled compound.  
yield:69%

Example 118.

- 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-dimethoxyphe-  
30 nyl)piperazine:  
Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:88%

35

Example 119.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2,3-xylyl)piperazine

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-(2,3-xylyl)piperazine were reacted by the same way with the example 1 to  
obtain the titled compound.  
5 yield:72%

Example 120.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-xylyl)piperazine  
:  
10 Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-(3,5-xylyl)piperazine were reacted by the same way with the example 1 to  
obtain the titled compound.  
yield:68%

15 Example 121.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2,5-xylyl)piperazine  
:  
Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-(2,5-xylyl)piperazine were reacted by the same way with the example 1 to  
20 obtain the titled compound.  
yield:72%

Example 122.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-hydroxy-4-met-  
25 hylphenyl)piperazine:  
Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-(2-hydroxy-4-methylphenyl)piperazine were reacted by the same way with  
the example 1 to obtain the titled compound.  
yield:77%

30

Example 123.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3-hydroxy 4-met-  
hoxylphenyl)piperazine:  
Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
35 1-(3-hydroxy-4-methoxyphenyl)piperazine were reacted by the same way  
with the example 1 to obtain the titled compound.  
yield:69%

## Example 124.

5 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(1-naphthyl)piperazine:

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-(1-naphthyl)piperazine were reacted by the same way with the example 1  
to obtain the titled compound.  
yield:74%

10

## Example 125.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(1-anthryl)piperazine:

15 Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)carbamate and  
1-(1-anthryl)piperazine were reacted by the same way with the example 1 to  
obtain the titled compound.  
yield:62%

## Example 126.

20 1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminothiocarbonyl]-4-(3-chlorophenyl)  
piperazine:

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)thiocarbamate and  
1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
25 yield:69%

## Example 127.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(3,5-dichlorophenyl)  
piperazine:

30 Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)thiocarbamate and  
1-(3,5-dichlorophenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:82%

35

## Example 128.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)  
piperazine:

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)thiocarbamate and



- 47 -

1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:70%

5 Example 129.

1-[(5,6-dimethyl-2-methoxypyridin-3-yl)aminothi carbonyl]-4-(3,5-dimethoxy-phenyl)piperazine:

Phenyl-N-(5,6-dimethyl-2-methoxypyridin-3-yl)thiocarbamate and 1-(3,5-dimethoxyphenyl)piperazine were reacted by the same way with the

10 example 1 to obtain the titled compound.

yield:69%

Example 130.

1-[(2-methoxy-5,6,7-trihydro-1-pyrinden-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl-N-(2-methoxy-5,6,7-trihydro-1-pyrinden-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:64%

20

Example 131.

1-[(2-methoxy-5,6,7-trihydro-1-pyrinden-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine:

Phenyl-N-(2-methoxy-5,6,7-trihydro-1-pyrinden-3-yl)carbamate and

25 1-(3-chlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:63%

Example 132.

30 1-[(2-methoxy-5,6,7-trihydro-1-pyrinden-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine:

Phenyl-N-(2-methoxy-5,6,7-trihydro-1-pyrinden-3-yl)carbamate and

1-(2-fluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

35 yield:59%

Example 133.

- 48 -

1-[(2-methoxy-5,6,7,8-tetrahydroisoquinolin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

5 Phenyl-N-(2-methoxy-5,6,7,8-tetrahydroisoquinolin-3-yl)carbamate and  
1-(2-methoxyphenyl)piperazine were reacted by the same way with the  
example 1 to obtain the titled compound.  
yield:64%

Example 134.

10 1-[(2-methoxy-5,6,7,8-tetrahydroisoquinolin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine:

Phenyl-N-(2-methoxy-5,6,7,8-tetrahydroisoquinolin-3-yl)carbamate and  
1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
15 yield:69%

Example 135.

1-[(2-methoxy-5,6,7,8-tetrahydroisoquinolin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine:

20 Phenyl-N-(2-methoxy-5,6,7,8-tetrahydroisoquinolin-3-yl)carbamate and  
1-(2-fluorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.  
yield:70%

25 Example 136.

1-[(5-isopropyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl-N-(5-isopropyl-2-methoxy-6-methylpyridin-3-yl)carbamate and  
1-(2-methoxyphenyl)piperazine were reacted by the same way with the  
30 example 1 to obtain the titled compound.  
yield:64%

Example 137.

35 1-[(5-isopropyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine:

Phenyl-N-(5-isopropyl-2-methoxy-6-methylpyridine-3-yl)carbamate and  
1-(3-chlorophenyl)piperazine were reacted by the same way with the example  
1 to obtain the titled compound.

- 49 -

yield:63%

Example 138.

5 1-[(5-isopropyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-fluorophenyl)piperazine:

Phenyl-N-(5-isopropyl-2-methoxy-6-methylpyridin-3-yl)carbamate and 1-(2-fluorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

10 yield:59%

Example 139.

1-[(2-methoxypyridin-3-yl)aminocarbonyl]-4-phenylpiperazine:

15 Phenyl-N-(2-methoxypyridin-3-yl)carbamate and 1-phenylpiperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:88%

Example 140.

20 1-[(2-methoxypyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine:

Phenyl-N-(2-methoxypyridin-3-yl)carbamate and 1-(2-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:86%

25 Example 141.

1-[(2-methoxypyridin-3-yl)aminocarbonyl]-4-(4-methoxyphenyl)piperazine:

Phenyl-N-(2-methoxypyridin-3-yl)carbamate and 1-(4-methoxyphenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

30 yield:85%

Example 142.

1-[(2-methoxypyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine:

35 Phenyl-N-(2-methoxypyridin-3-yl)carbamate and 1-(3-chlorophenyl)piperazine were reacted by the same way with the example 1 to obtain the titled compound.

yield:72%

## Example 143.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-[(3-propargyl-amino)pyridin-2-yl]piperazine:

- 5    Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)carbamate                      and  
1-[(3-propargylamino)pyridine-2-yl]piperazine were reacted by the same way  
with the example 1 to obtain the titled compound.  
yield:61%

## 10    Example 144.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)methylaminocarbonyl]-4-[(3-propargylamino)pyridin-2-yl]piperazine:

- Phenyl-N-(5-ethyl-2-methoxy-6-methylpyridin-3-yl)methylcarbamate                      and  
1-[(3-propargylamino)pyridin-2-yl]piperazine were reacted by the same way  
15    with the example 1 to obtain the titled compound.  
yield:74%

## Example 145.

- 1-[(5-ethyl-6-methyl-2(1H)-pyridinon-3-yl)methylaminocarbonyl]-4-[(3-propa-  
20    -rgylamino)pyridin-2-yl]piperazine:

Phenyl-N-[5-ethyl-6-methyl-2(1H)-pyridinon-3-yl]methylcarbamate                      and  
1-[(3-propargylamino)pyridin-2-yl]piperazine were reacted by the same way  
with the example 1 to obtain the titled compound.  
yield:77%

25

## Example 146.

1-[(5-ethyl-6-methyl-2(1H)-pyridinon-3-yl)methylaminocarbonyl]-4-[(3-dibe-  
nzylamino)pyridin-2-yl]piperazine:

- Phenyl-N-[5-ethyl-6-methyl-2(1H)-pyridinon-3-yl]methylcarbamate                      and  
30    1-[(3-dibenzylamino)pyridine-2-yl]piperazine were reacted by the same way  
with the example 1 to obtain the titled compound.  
yield:65%

## Example 147.

- 35    1-[(5-isopropyl-6-methyl-2(1H)-pyridinon-3-yl)methylaminocarbonyl]-4-[(3-ethylamino)pyridin-2-yl]piperazine:

Phenyl-N-[5-ethyl-6-methyl-2(1H)-pyridinon-3-yl]methylcarbamate                      and  
1-[(3-ethylamino)pyridin-2-yl]piperazine were reacted by the same way with

- 51 -

the example 1 to obtain the titled compound.  
yield:62%

5 Example 148.

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-[(2-methoxyphenyl)piperazine-2-yl]piperazine salt of hydrochloride:

After 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(2-methoxyphenyl)piperazine(5.0g, 13mmol) was dissolved in 400ml of diethylether,  
10 the mixture was saturated by hydrogen chloride gas at 0℃ and stirred for 30 minutes and purified to obtain the titled compound.  
yield:98%

Example 149.

15 1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine salt of hydrochloride:

1-[(5-ethyl-2-methoxy-6-methylpyridin-3-yl)aminocarbonyl]-4-(3-chlorophenyl)piperazine was reacted by the same way with the example 148 to obtain the titled compound.

20 yield:98%

25

30

35

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
1	C <sub>21</sub> H <sub>25</sub> N <sub>3</sub> O <sub>3</sub> : theoretical, C, 65.60, H, 7.34, N, 14.57 experimental, C, 66.10, H, 7.25, N, 14.57	1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55 (2H, q, J=7.5Hz), 3.11(4H, t, J=4.6Hz), 3.69(4H, t, J=5.0Hz), 3.88(1H, s), 3.98 (3H, s), 6.89(1H, s), 6.94(3H, m), 7.05 (1H, m), 8.21(1H, s).	115-118°C
2		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55 (2H, q, J=7.5Hz), 3.26(4H, t, J=4.5Hz), 3.68(4H, t), 3.98(3H, s), 6.91(1H, s), 6.95(4H, m), 7.28(1H, m), 8.35(1H, s).	102-103°C
3		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55 (2H, q, J=8.0Hz), 3.12(4H, t), 3.63 (4H, t), 3.78(3H, s), 3.97(3H, s), 6.85 (1H, s), 6.87(2H, m), 6.97(2H, m), 8.19(1H, s).	84-85°C
4		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55 (2H, q, J=7.5Hz), 3.04(4H, t), 3.68 (4H, t), 3.79(3H, s), 3.86(3H, s), 3.97 (3H, s), 6.43(1H, d), 6.50(1H, s), 6.87 (1H, d), 6.92(1H, s), 8.21(1H, s).	116-119°C
5		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55 (2H, q, J=7.5Hz), 3.14(4H, t), 3.68 (4H, t), 3.85(3H, s), 3.88(3H, s), 3.97 (3H, s), 6.49(1H, d), 6.60(1H, s), 6.82 (1H, d), 6.92(1H, s), 8.21(1H, s).	103-104°C
6	C <sub>22</sub> H <sub>30</sub> N <sub>4</sub> O <sub>4</sub> : theoretical, C, 63.75, H, 7.30, N, 13.52 experimental, C, 63.81, H, 7.31, N, 13.32	1.17(2H, q, J=7.5Hz), 2.37(3H, s), 2.55 (2H, q, J=7.5Hz), 3.27(4H, t), 3.74 (4H, t), 3.79(6H, s), 3.98(3H, s), 6.09 (1H, s), 6.16(2H, s), 6.90(1H, s), 8.19(1H, s)	126-127°C
7		1.16(3H, t, J=7.5Hz), 2.37(3H, s), 2.55 (2H, q, J=7.5Hz), 3.20(4H, t, J=4.7Hz), 3.69(4H, t), 3.80(3H, s), 3.86(6H, s), 3.98(3H, s), 6.20(2H, s), 8.19(1H, s).	oil phase
8	C <sub>22</sub> H <sub>30</sub> N <sub>4</sub> O <sub>3</sub> : theoretical, C, 66.31, H, 7.59, N, 14.06 experimental, C, 66.13, H, 7.72, N, 13.78	1.17(3H, q, J=7.5Hz), 1.48(3H, t, J=6.95 Hz), 2.37(3H, s), 2.56(2H, q, J=7.5Hz), 3.14(4H, t, J=4.7Hz), 3.69(4H, t, J=4.6 Hz), 3.98(3H, s), 4.10(2H, q), 6.87(1H, s), 6.92(3H, m), 7.01(1H, m), 8.21(1H, s)	96-97°C

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
9	-	1.16(3H, t, J=7.5Hz), 2.36(3H, s), 2.54(2H, q, J=7.5Hz), 3.14(4H, t), 3.45(4H, t), 3.95(3H, s), 6.83(1H, s), 6.92(2H, m), 7.03(5H, m), 7.15(1H, m), 7.31(2H, m), 8.16(1H, s).	167-168°C
10	-	1.17(3H, t, J=7.5Hz), 2.38(3H, s), 2.55(2H, q, J=7.5Hz), 3.27(4H, t, J=5.0Hz), 3.70(4H, t), 3.99(3H, s), 6.55(1H, d), 6.67(1H, s), 6.91(1H, m), 7.02(2H, d), 7.11(1H, m), 7.24(2H, m), 7.34(2H, m), 8.19(1H, s).	oil phase
11	-	1.19(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.14(4H, t), 3.68(4H, t), 3.97(3H, s), 6.92(1H, s), 6.94(2H, m), 7.06(2H, m), 8.20(1H, s).	120-121°C
12	-	1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.16(4H, t, J=5.0Hz), 3.66(4H, t, J=5.1Hz), 3.98(3H, s), 6.89(1H, s), 6.91(2H, m), 6.99(2H, m), 8.19(1H, s).	oil phase
13	C <sub>20</sub> H <sub>24</sub> N <sub>2</sub> O <sub>2</sub> F <sub>2</sub> : theoretical, C, 61.53, H, 6.20, N, 14.35 experimental, C, 61.31, H, 6.27, N, 14.04	1.17(3H, t, J=7.5Hz), 2.38(3H, s), 2.56(2H, q), 3.29(4H, t, J=5.5Hz), 3.68(4H, t, J=5.5Hz), 3.99(3H, s), 6.28(1H, m), 6.32(2H, d), 6.89(1H, s), 8.18(1H, s).	115-116°C
14	-	1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.56(2H, q, J=7.5Hz), 3.31(4H, t, J=5.0Hz), 3.69(4H, t, J=5.0Hz), 3.98(3H, s), 6.91(1H, d), 7.09(1H, d), 7.12(2H, m), 7.39(1H, m), 8.19(1H, s).	113-115°C
15	-	1.19(3H, t, J=7.5Hz), 2.38(3H, s), 2.56(2H, q, J=7.0Hz), 3.10(4H, t, J=5.0Hz), 3.69(4H, t, J=5.0Hz), 3.99(3H, s), 6.82(1H, d), 6.91(1H, s), 7.04(2H, m), 7.40(1H, m), 8.22(1H, s).	97-99°C
16	C <sub>20</sub> H <sub>25</sub> N <sub>4</sub> O <sub>2</sub> Cl <sub>1</sub> : theoretical, C, 61.77, H, 6.48, N, 14.41 experimental, C, 61.79, H, 6.54, N, 14.26	1.17(3H, t, J=7.5Hz), 2.38(3H, s), 2.55(2H, q, J=7.5Hz), 3.26(4H, t, J=5.0Hz), 3.66(4H, t, J=5.0Hz), 3.98(3H, s), 6.79(1H, d), 6.86(1H, d), 6.89(2H, d), 7.19(1H, m), 8.18(1H, m).	104-105°C

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
17	-	1.17(3H, t, J=7.5Hz), 2.38(3H, s), 2.51(2H, q, J=5.0Hz), 3.48(4H, t, J=5.0Hz), 3.75(4H, t, J=5.0Hz), 3.98(3H, s), 6.84(3H, m), 8.35(1H, s).	74-75°C
18		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.54(2H, q, J=7.5Hz), 3.26(4H, t, J=5.0Hz), 3.77(4H, t, J=5.0Hz), 3.98(3H, s), 6.85(1H, s), 6.97(2H, m), 7.31(1H, m), 8.19(1H, s).	85-86°C
19		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.26(4H, t), 3.69(4H, t), 3.98(3H, s), 6.84(1H, m), 6.91(1H, s), 6.96(2H, m), 7.29(1H, m), 8.19(1H, s).	oil phase
20		1.18(3H, t, J=7.5Hz), 2.39(3H, s), 2.56(2H, q, J=7.0Hz), 3.28(4H, t, J=4.5Hz), 3.65(4H, t, J=4.5Hz), 3.99(3H, s), 6.90(1H, s), 7.26(2H, m), 8.23(1H, s).	162-163°C
21		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.27(4H, t), 3.69(4H, t), 3.98(3H, s), 6.84(1H, s), 6.98(3H, m), 7.39(1H, m), 8.35(1H, s).	94-94°C
22		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.56(2H, q, J=7.5Hz), 3.27(4H, t), 3.74(4H, t), 3.98(3H, s), 6.91(1H, s), 6.98(3H, m), 7.46(1H, m), 8.19(1H, s).	99-101°C
23		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.25(4H, t, J=5.0Hz), 3.67(4H, t, J=5.0Hz), 3.98(3H, s), 6.94(2H, m), 7.29(2H, m), 8.21(1H, s).	97-98°C
24		1.17(3H, t, J=7.5Hz), 2.38(3H, s), 2.55(2H, q, J=7.5Hz), 3.48(4H, t, J=5.0Hz), 3.75(4H, t, J=5.0Hz), 3.96(3H, s), 6.84(2H, m), 7.22(1H, s), 8.18(1H, s).	oil phase



- 55 -

example number	elementary analysis	$^1\text{H}$ NMR (500MHz, $\text{CDCl}_3$ ) $\delta$	melting point
25	-	1.17(3H, t, J=7.5Hz), 2.38(3H, s), 2.55(2H, q, J=7.5Hz), 3.48(4H, t, J=5.0Hz), 3.75(4H, t, J=4.5Hz), 3.96(3H, s), 6.81(1H, s), 6.84(2H, m), 7.22(1H, s), 8.18(1H, s).	oil phase
26	-	1.18(3H, t, J=7.5Hz), 2.34(3H, s), 2.37(3H, s), 2.57(2H, q, J=7.5Hz), 2.96(4H, t, J=5.0Hz), 3.65(4H, t, J=4.5Hz), 3.97(3H, s), 6.92(1H, s), 7.02(2H, m), 7.17(2H, m), 8.21(1H, s).	129-130°C
27	-	1.17(3H, t, J=7.5Hz), 2.28(3H, s), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.18(4H, t, J=5.0Hz), 3.66(4H, t, J=5.0Hz), 3.97(3H, s), 6.87(2H, m), 6.91(1H, s), 7.11(2H, m), 8.19(1H, s).	oil phase
28	$\text{C}_{22}\text{H}_{30}\text{N}_4\text{O}_2$ : theoretical, C, 69.08, H, 7.91, N, 14.65 experimental, C, 68.48, H, 8.04, N, 14.04	1.18(3H, t, J=7.5Hz), 2.25(3H, s), 2.28(3H, s), 2.37(3H, s), 2.56(2H, q, J=7.5 Hz), 2.95(4H, t), 3.65(4H, t), 3.97(3H, s), 6.89(2H, m), 7.07(1H, m), 8.21(1H, s).	99-100°C
29	$\text{C}_{22}\text{H}_{30}\text{N}_4\text{O}_2$ : theoretical, C, 69.08, H, 7.91, N, 14.65 experimental, C, 69.31, H, 7.82, N, 14.14	1.17(3H, t, J=7.5Hz), 2.29(6H, s), 2.44(3H, s), 2.55(2H, q), 3.22(4H, t, J=4.5 Hz), 3.73(4H, t, J=4.5Hz), 3.98(3H, s), 6.42(3H, s), 6.90(1H, s), 8.35(1H, s).	83-84°C
30	-	1.18(3H, t, J=8.0Hz), 2.33(6H, s), 2.39(3H, s), 2.53(2H, q, J=7.5Hz), 3.15(4H, t, J=5.0Hz), 3.60(4H, t, J=5.0Hz), 4.00(3H, s), 6.91(1H, s), 6.99(3H, m), 8.24(1H, s).	122-123°C
31	-	1.17(3H, t, J=7.5Hz), 1.22(3H, s), 1.23(3H, s), 2.37(3H, s), 2.55(2H, q, J=7.5 Hz), 2.87(1H, m), 3.21(4H, t), 3.67(4H, t), 3.97(3H, s), 6.90(3H, m), 7.17(2H, d), 8.35(1H, s).	99-100°C
32	-	1.15(3H, t, J=7.5Hz), 1.22(3H, s), 1.23(3H, s), 2.38(3H, s), 2.94(4H, t), 3.07(1H, m), 3.16(4H, t), 4.00(3H, s), 6.84(1H, s), 7.16(3H, m), 7.30(1H, m), 8.22(1H, s).	137-139°C

- 56 -

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
33	-	0.91(3H, t, J=7.5Hz), 1.17(3H, t, J=7.5Hz), 1.35(2H, m), 1.59(2H, m), 2.37(3H, s), 2.55(4H, q, J=4.0Hz), 3.20 (4H, t, J=5.0 Hz), 3.66(4H, t, J=5.0Hz), 3.97(3H, s), 6.82(2H, m), 6.88(1H, s), 7.11(2H, m), 8.19(1H, s).	72-73°C
34	-	1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.56(3H, s), 2.57(2H, q, J=7.5Hz), 3.55(4H, t), 3.69(4H, t), 3.98(3H, s), 6.88(3H, m), 7.91(2H, m), 8.18(1H, s).	149-150°C
35	-	1.15(3H, t, J=7.5Hz), 2.37(3H, s), 2.54 (2H, q, J=7.5Hz), 2.89(4H, t, J=4.8Hz), 3.38(4H, t, J=4.8Hz), 3.95(3H, s), 6.78 (1H, s), 7.03(1H, d), 7.12(1H, m), 7.31 (3H, m), 7.41(2H, m), 7.63(2H, m), 8.17(1H, s).	oil phase
36	-	1.18(3H, t, J=7.5Hz), 2.38(3H, s), 2.56 (2H, q, J=7.5Hz), 3.32(4H, t), 3.72(4H, t), 3.99(3H, s), 6.92(1H, s), 7.04(2H, m), 7.40(2H, m), 7.57(5H, m), 8.20(1H, s).	160-161°C
37	-	1.18(3H, t, J=7.5Hz), 2.38(3H, s), 2.97 (4H, t), 3.70(4H, t), 3.98(1H, s), 6.92 (2H, m), 7.11(2H, m), 8.19(1H, s).	oil phase
38	C <sub>20</sub> H <sub>22</sub> N <sub>4</sub> O <sub>3</sub> : theoretical, C, 64.85, H, 7.07, N, 15.12 experimental, C, 59.89, H, 7.17, N, 14.73	1.16(3H, t, J=7.5Hz), 2.39(3H, s), 3.23 (4H, t, J=5.0Hz), 3.67(4H, t), 3.98(3H, s), 6.39(1H, d), 6.45(1H, s), 6.51(1H, d), 6.90(1H, s), 7.13(1H, m), 8.17(1H, s).	148-149°C
39	-	1.18(3H, t, J=7.5Hz), 2.37(3H, s), 2.55 (2H, q, J=7.5Hz), 3.16(4H, t), 3.73(4H, t), 3.98(3H, s), 6.80(2H, m), 6.91(2H, m), 8.17(1H, s).	103-104°C
40	-	1.17(3H, t, J=7.5Hz), 2.29(3H, s), 2.38 (3H, s), 2.56(2H, q, J=7.5Hz), 3.24(4H, t), 3.72(4H, t), 3.99(3H, s), 6.90(1H, s), 7.03(4H, m), 8.21(1H, s).	161-162°C

- 57 -

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
41	C <sub>22</sub> H <sub>25</sub> N <sub>4</sub> O <sub>4</sub> : theoretical, C, 64.06, H, 6.84, N, 13.58 experimental, C, 64.31, H, 13.50, N, 7.00	1.17(3H, t, J=7.5Hz), 2.29(3H, s), 2.38(3H, t), 2.56(2H, q, J=7.5Hz), 3.28(4H, t, J=5.0Hz), 3.68(4H, t), 3.99(3H, s), 6.65(2H, m), 6.84(1H, d), 6.89(1H, s), 7.30(1H, m), 8.19(1H, s).	90-91°C
42		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.18(4H, t), 3.68(4H, t), 3.99(3H, s), 6.89(2H, m), 6.99(2H, m), 8.19(1H, s).	oil phase
43		1.18(3H, t, J=7.5Hz), 2.37(3H, s), 2.54(2H, q, J=7.5Hz), 2.89(3H, s), 2.97(4H, t), 3.65(4H, t), 3.96(3H, s), 6.77(2H, m), 6.94(1H, s), 7.03(1H, d), 7.13(1H, m).	108-109°C
44		1.17(3H, t, J=7.5Hz), 2.26(3H, s), 2.57(2H, q), 3.17(4H, t), 3.79(1H, d), 4.00(3H, s), 6.91(1H, s), 7.09(1H, d), 7.42(1H, m), 7.50(3H, m), 7.59(1H, d), 7.84(1H, d).	159-160°C
45		1.17(3H, t, J=7.5Hz), 2.47(3H, s), 2.56(2H, q), 3.04(4H, t), 4.05(3H, s), 6.97(1H, s), 7.49(4H, m), 8.01(2H, m), 8.27(2H, m), 8.43(1H, s).	oil phase
46		1.18(3H, t, J=7.5Hz), 2.26(3H, s), 2.39(3H, s), 2.56(2H, q, J=7.5Hz), 2.82(2H, m), 3.20(2H, m), 3.46(2H, m), 3.78(3H, s), 3.99(2H, m), 4.14(3H, s), 6.71(1H, d), 6.82(1H, d), 6.91(1H, s), 7.04(1H, m), 8.25(1H, s).	151-152°C
47	C <sub>22</sub> H <sub>30</sub> N <sub>4</sub> O <sub>3</sub> : theoretical, C, 66.31, H, 7.59, N, 14.06 experimental, C, 66.46, H, 7.75, N, 13.71	1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.49(3H, s), 2.55(2H, q, J=7.5Hz), 3.11(4H, t), 3.77(4H, t), 3.86(3H, s), 3.96(3H, s), 6.77(3H, m), 8.37(1H, s).	90-91°C
48	C <sub>22</sub> H <sub>30</sub> N <sub>4</sub> O <sub>3</sub> : theoretical, C, 66.31, H, 7.59, N, 14.06 experimental, C, 65.24, H, 7.49, N, 13.91	1.17(3H, t, J=7.5Hz), 2.23(3H, s), 2.37(3H, s), 2.38(3H, s), 2.53(2H, q, J=7.5Hz), 2.95(4H, t, J=4.8Hz), 3.65(4H, t, J=4.6Hz), 3.96(3H, s), 3.98(3H, s), 6.57(2H, m), 6.84(1H, s), 7.03(1H, s), 8.20(1H, s).	84-85°C

- 58 -

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
49		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.12(4H, t), 3.70(4H, t), 3.89(3H, s), 3.97(3H, s), 6.80(2H, m), 6.94(1H, s), 8.21(1H, s).	97-98°C
50		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.57(2H, q, J=7.5Hz), 3.27(4H, t), 3.69(4H, t), 3.80(3H, s), 3.98(3H, s), 6.50(1H, m), 6.90(1H, s), 7.54(1H, m), 7.71(1H, m), 8.19(1H, s).	oil phase
51		1.19(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.13(4H, t), 3.67(4H, t), 3.78(3H, s), 3.97(3H, s), 6.87(3H, m), 8.19(1H, s).	94-95°C
52		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.15(4H, t), 3.69(4H, t), 3.83(3H, s), 3.98(3H, s), 6.46(1H, d), 6.69(1H, d), 6.90(1H, s), 8.18(1H, s).	149-150°C
53		1.17(3H, t, J=7.5Hz), 2.31(3H, s), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.14(4H, t), 3.66(4H, t), 3.79(3H, s), 3.95(3H, s), 6.77(1H, s), 6.92(2H, m), 8.18(1H, s).	128-129°C
54		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.56(2H, q, J=7.5Hz), 3.19(4H, t), 3.73(4H, t), 3.93(3H, s), 3.98(3H, s), 6.82(1H, s), 6.84(2H, m), 7.31(2H, m), 7.42(2H, m), 7.53(2H, m), 8.21(1H, s).	134-135°C
55	C <sub>21</sub> H <sub>27</sub> N <sub>4</sub> O <sub>3</sub> Cl <sub>1</sub> : theoretical, C, 60.20, H, 6.50, N, 13.37 experimental, C, 59.33, H, 6.16, N, 12.80	1.17(3H, t, J=7.5Hz), 2.23(3H, s), 2.38(3H, s), 2.56(2H, q, J=7.5Hz), 2.95(4H, t, J=5.0Hz), 3.66(4H, t), 3.99(3H, s), 6.58(1H, d), 6.64(1H, d), 6.91(1H, s), 7.05(1H, m), 8.21(1H, s).	188-189°C
56	C <sub>21</sub> H <sub>28</sub> N <sub>4</sub> O <sub>3</sub> : theoretical, C, 65.60, H, 7.34, N, 14.57 experimental, C, 65.65, H, 7.32, N, 14.40	1.18(3H, t, J=8.0Hz), 2.36(3H, s), 2.41(3H, s), 2.57(2H, q, J=7.5Hz), 2.93(2H, m), 3.20(2H, m), 3.43(2H, m), 3.99(3H, s), 4.11(2H, m), 6.60(1H, d), 6.83(2H, d), 6.93(1H, s), 7.15(1H, m), 8.23(1H, s).	208-211°C

- 59 -

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
57	-	1.18(3H, t, J=7.5Hz), 2.29(3H, s), 2.38(3H, s), 2.56(2H, q, J=7.5Hz), 2.97(4H, t), 3.71(4H, t), 3.98(3H, s), 6.69(1H, d), 6.82(1H, s), 6.90(1H, s), 7.05(1H, d), 8.18(1H, s).	192-193°C
58	-	1.13(3H, t, J=7.5Hz), 2.24(3H, s), 2.55(2H, q, J=7.5Hz), 3.48(4H, t, J=5.0Hz), 3.75(4H, t, J=5.0Hz), 3.97(3H, s), 6.89(2H, m), 7.20(1H, s), 8.35(1H, s).	74-75°C
59	-	1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.04(4H, t, J=5.0Hz), 3.68(4H, t, J=5.0Hz), 3.98(3H, s), 6.94(2H, m), 6.98(1H, m), 8.19(1H, s).	85-86°C
60	C <sub>22</sub> H <sub>30</sub> N <sub>4</sub> O <sub>3</sub> : theoretical, C, 66.31, H, 7.59, N, 14.06 experimental, C, 65.38, H, 7.65, N, 13.74	1.11(3H, t, J=7.5Hz), 2.38(3H, s), 2.54(2H, q, J=7.5Hz), 3.05(4H, t, J=5.0Hz), 3.53(4H, t, J=4.5Hz), 3.86(3H, s), 3.95(3H, s), 4.33(2H, d), 6.86(1H, d), 6.93(2H, m), 7.01(1H, m), 7.25(1H, s).	oil phase
61	C <sub>21</sub> H <sub>27</sub> N <sub>4</sub> O <sub>2</sub> F <sub>1</sub> : theoretical, C, 65.27, H, 7.04, N, 14.50 experimental, C, 65.87, H, 7.35, N, 14.48	1.14(3H, t, J=7.5Hz), 2.40(3H, s), 2.54(2H, q, J=7.5Hz), 3.04(4H, t, J=5.0Hz), 3.52(4H, t, J=5.0Hz), 3.96(3H, s), 4.33(2H, d), 6.92(2H, m), 7.06(2H, m), 7.32(1H, s).	oil phase
62	-	1.16(3H, t, J=7.5Hz), 2.40(3H, s), 2.54(2H, q, J=7.5Hz), 3.07(4H, t, J=5.0Hz), 3.50(4H, t, J=5.0Hz), 3.95(3H, s), 4.34(2H, d), 6.85(2H, m), 6.97(2H, m), 7.32(1H, s).	oil phase
63	-	1.15(3H, t, J=8.0Hz), 2.38(3H, s), 2.54(2H, q, J=7.5Hz), 3.16(4H, t, J=5.0Hz), 3.49(4H, t, J=5.0Hz), 3.96(3H, s), 4.33(2H, d), 6.75(1H, m), 6.85(2H, m), 7.15(1H, m), 7.46(2H, s).	oil phase
64	-	1.15(3H, t, J=7.5Hz), 2.40(3H, s), 2.53(2H, q, J=7.5Hz), 2.76(2H, t, J=6.5Hz), 3.05(4H, t, J=4.8Hz), 3.47(6H, m), 3.93(3H, s), 6.87(2H, m), 6.97(2H, m), 7.26(1H, s).	oil phase

- 60 -

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
65	-	1.14(3H, t, J=7.5Hz), 2.43(3H, s), 2.51(2H, q, J=7.5Hz), 2.76(2H, m), 3.00(4H, t, J=5.0Hz), 3.44(2H, m), 3.50(4H, t), 3.87(3H, s), 3.93(3H, s), 6.72(1H, m), 6.92(2H, m), 7.01(1H, m), 7.16(1H, s).	oil phase
66		1.16(3H, t, J=7.5Hz), 1.80(2H, q), 2.40(3H, s), 2.53(2H, q), 2.58(2H, t), 3.26(2H, q), 3.89(3H, s), 3.93(3H, s), 6.92(4H, m), 7.16(1H, s).	oil phase
67		1.15(3H, t, J=7.5Hz), 1.38(2H, m), 1.58(4H, m), 2.39(3H, s), 2.52(4H, m), 3.06(4H, t), 3.25(2H, m), 3.55(4H, t), 3.87(3H, s), 3.91(3H, s), 6.88(2H, m), 6.94(2H, m), 7.46(1H, s).	128-129°C
68		1.15(3H, t, J=7.5Hz), 1.33(6H, m), 1.52(2H, m), 2.39(3H, s), 2.52(4H, m), 3.05(4H, t), 3.25(2H, m), 3.54(4H, t), 3.87(3H, s), 3.90(3H, s), 6.87(2H, m), 6.93(2H, m), 7.10(1H, s).	118-120°C
69		1.20(3H, t), 2.39(3H, s), 2.58(2H, q), 2.83(4H, t), 3.20(6H, brs), 3.90(3H, s), 3.98(3H, s), 7.00(4H, m), 8.40(1H, s).	164-165°C
70		1.18(3H, t), 2.39(3H, s), 2.56(2H, q), 2.77(4H, t), 3.21(2H, m), 3.28(4H, t), 6.82(2H, m), 6.90(1H, s), 7.19(1H, m), 8.37(1H, s).	120-123°C
71		1.18(3H, t), 2.39(3H, s), 2.56(2H, q), 2.81(4H, t), 3.20(6H, brs), 3.97(3H, s), 7.04(4H, m), 8.38(1H, s).	139-140°C
72		1.16(3H, t, J=7.5Hz), 2.36(3H, s), 2.54(6H, m), 3.96(3H, s), 6.85(1H, s), 7.33(5H, s).	96-97°C

- 61 -

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
73		1.16(3H, t, J=7.5Hz), 2.36(3H, s), 2.52(6H, m), 3.53(6H, m), 3.81(3H, s), 3.95(3H, s), 6.84(1H, s), 6.88(2H, m), 7.27(2H, m), 8.16(1H, s).	96-98°C
74		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.52(2H, q), 2.65(4H, t), 3.61(6H, m), 3.83(3H, s), 3.95(3H, s), 6.83(1H, s), 6.90(2H, m), 6.97(2H, m), 8.15(1H, s).	83-84°C
75		1.16(3H, t, J=7.5Hz), 2.37(3H, s), 2.54(6H, m), 3.53(6H, m), 3.97(3H, s), 6.85(1H, s), 7.02(2H, m), 7.32(2H, m), 8.17(1H, s).	74-75°C
76		1.17(3H, t, J=7.5Hz), 1.39(3H, t, J=7.0Hz), 2.35(3H, s), 2.55(2H, q, J=5.0Hz), 3.13(4H, t, J=4.6Hz), 3.68(4H, t, J=4.6Hz), 3.89(3H, s), 4.42(2H, q, J=9.3Hz), 6.90(1H, d), 6.96(2H, m), 7.04(1H, m), 8.21(1H, s).	114-115°C
77		1.17(3H, t, J=7.5Hz), 1.40(3H, t, J=7.0Hz), 2.38(3H, s), 2.55(2H, q, J=7.5Hz), 3.14(4H, t, J=4.5Hz), 3.68(4H, t, J=4.5Hz), 4.43(2H, q, J=7.0Hz), 6.96(2H, m), 7.08(2H, m), 8.19(1H, s).	126-127°C
78		1.17(3H, t, J=7.5Hz), 1.40(3H, t, J=7.5Hz), 2.35(3H, s), 2.55(2H, q, J=7.5Hz), 3.27(4H, t, J=5.0Hz), 3.66(4H, t, J=5.0Hz), 4.43(2H, q, J=7.0Hz), 6.79(1H, d), 6.81(1H, d), 6.86(1H, s), 6.94(1H, s), 7.19(1H, m), 8.18(1H, s).	101-102°C
79		1.17(3H, t, J=7.5Hz), 1.40(3H, t, J=7.0Hz), 1.49(3H, t, J=6.9Hz), 2.35(3H, s), 2.55(2H, q), 3.14(4H, t), 3.68(4H, t), 4.10(2H, q), 4.44(2H, q), 6.87(1H, d), 6.92(2H, m), 6.96(1H, s), 7.00(1H, m), 8.20(1H, s).	oil phase
80		1.22(3H, t, J=7.5Hz), 2.31(3H, s), 2.58(2H, q, J=7.5Hz), 3.08(4H, t), 3.66(4H, t), 3.88(3H, s), 6.96(3H, m), 7.13(2H, m), 7.23(2H, m), 7.36(2H, m), 8.36(1H, s).	104-105°C

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
81	-	1.22(3H, t, J=7.5Hz), 2.31(3H, s), 2.60(2H, q, J=7.5Hz), 3.22(4H, t), 3.66(4H, t), 3.88(3H, s), 6.93(1H, s), 6.96(3H, m), 7.13(2H, m), 7.23(2H, m), 7.36(2H, m), 8.36(1H, s).	120-121°C
82		1.22(3H, t, J=7.5Hz), 2.29(3H, s), 2.34(3H, s), 2.60(2H, q, J=7.5Hz), 3.24(4H, t, J=5.0Hz), 3.63(4H, t, J=4.5Hz), 6.62(2H, m), 6.80(1H, d), 6.93(1H, s), 7.10(2H, m), 7.17(1H, m), 7.27(1H, m), 7.46(2H, m), 8.34(1H, s).	52-53°C
83		1.22(3H, t, J=7.5Hz), 2.31(3H, s), 2.60(2H, q), 3.11(4H, t, J=4.8Hz), 3.65(4H, t, J=4.8Hz), 6.99(3H, m), 7.09(4H, m), 7.36(2H, m), 8.35(1H, s).	166-167°C
84		1.23(3H, t, J=7.5Hz), 2.28(3H, s), 2.31(3H, s), 2.60(2H, q, J=7.5Hz), 3.19(4H, t, J=5.0Hz), 3.95(4H, t), 6.55(3H, m), 6.94(1H, s), 7.09(2H, m), 7.20(1H, m), 7.38(2H, m), 8.35(1H, s).	oil phase
85		1.25(3H, t, J=7.2Hz), 2.30(3H, s), 2.60(2H, q, J=7.5Hz), 3.21(4H, t, J=5.2Hz), 3.62(4H, t), 3.77(6H, s), 6.08(3H, m), 7.13(2H, m), 6.93(1H, s), 7.16(1H, m), 7.36(2H, m), 8.34(1H, s).	94-95°C
86		1.19(3H, t, J=7.5Hz), 2.37(3H, s), 2.55(2H, q, J=7.5Hz), 3.26(4H, t, J=5.0Hz), 3.78(4H, t, J=6.0Hz), 3.98(3H, s), 6.91(1H, s), 6.97(2H, m), 7.31(1H, m), 8.91(1H, s).	156-157°C
87	-	1.22(3H, t, J=8.0Hz), 2.31(3H, s), 2.60(2H, q, J=7.5Hz), 3.10(4H, t), 3.66(4H, t), 3.99(3H, s), 6.79(1H, m), 6.91(1H, s), 6.93(2H, m), 7.10(2H, m), 7.16(1H, m), 7.38(2H, m), 8.34(1H, s).	117-118°C
88		1.23(3H, t, J=7.5Hz), 2.18(3H, s), 2.60(2H, q, J=7.5Hz), 3.22(4H, t, J=4.5Hz), 3.95(4H, t), 6.40(1H, m), 6.52(2H, m), 7.13(2H, m), 7.37(2H, m), 8.32(1H, s).	92-93°C



example number	elementary analysis	$^1\text{H}$ NMR (500MHz, $\text{CDCl}_3$ ) $\delta$	melting point
89		1.24(3H, t, J=7.5Hz), 2.52(3H, s), 2.66(2H, q, J=8.0Hz), 3.21(4H, t), 3.45(3H, s), 3.82(4H, t), 4.12(3H, s), 7.02(4H, m), 7.43(1H, s).	185-186°C
90		1.25(3H, t, J=7.5Hz), 2.52(3H, s), 2.65(2H, q), 3.45(3H, s), 3.89(6H, s), 6.95(3H, m), 7.43(1H, s).	102-103°C
91		1.22(3H, t, J=7.5Hz), 2.53(3H, s), 2.66(2H, q, J=7.5Hz), 3.35(4H, t), 3.47(3H, s), 3.81(4H, t), 4.23(1H, q, J=5.7Hz), 6.88(2H, m), 6.94(1H, s), 7.22(2H, m), 7.71(1H, s).	oil phase
92		1.22(3H, t, J=7.5Hz), 2.49(3H, s), 2.63(2H, q, J=8.0Hz), 3.11(4H, t, J=5.0Hz), 3.70(4H, t, J=5.0Hz), 3.72(6H, s), 6.68(1H, m), 6.88(2H, m), 7.05(1H, m), 7.88(1H, s), 8.23(1H, s).	161-162°C
93		1.21(3H, t, J=7.5Hz), 2.42(3H, s), 2.63(2H, q, J=7.5Hz), 3.24(4H, t, J=5.0Hz), 3.67(4H, t, J=5.0Hz), 3.78(6H, s), 6.05(1H, s), 6.09(2H, s), 7.89(1H, s), 8.26(1H, s).	179-180°C
94		1.20(3H, t, J=7.5Hz), 2.40(3H, s), 2.57(2H, q, J=7.5Hz), 3.02(4H, t), 3.09(4H, t), 3.28(4H, t), 3.68(4H, t), 6.80(2H, d), 6.82(1H, d), 6.90(1H, s), 7.22(1H, m), 8.22(1H, s).	oil phase
95		1.20(3H, t, J=7.5Hz), 1.48(9H, s), 2.39(3H, s), 2.58(2H, q), 2.95(4H, t), 3.28(4H, t), 3.57(4H, t), 3.67(4H, t), 6.79(1H, dd), 6.87(1H, dd), 7.21(1H, m), 7.26(1H, s), 8.24(1H, s).	188-189°C
96	-	1.20(3H, t, J=7.5Hz), 1.48(9H, s), 2.39(3H, s), 2.58(2H, q), 2.95(4H, t), 3.12(4H, t), 3.57(4H, t), 3.70(4H, t), 3.91(3H, s), 6.94(3H, m), 7.06(1H, m), 7.58(1H, s), 8.25(1H, s).	152-153°C

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
97	C <sub>21</sub> H <sub>28</sub> N <sub>4</sub> O <sub>2</sub> S <sub>1</sub> : theoretical. C, 62.97, H, 7.05, N, 13.99, S, 8.00 experimental. C, 62.61, H, 6.96, N, 14.08, S, 7.77	1.19(3H, t, J=7.5Hz), 2.39(3H, s), 2.57(2H, q, J=7.5Hz), 3.16(4H, t, J=5.0Hz), 3.89(3H, s), 3.96(3H, s), 4.10(4H, t, J=4.5Hz), 6.89(1H, m), 6.93(2H, m), 7.04(1H, m), 8.11(1H, s).	133-134°C
98		1.17(3H, t), 2.47(3H, s), 2.55(2H, q, J=7.5Hz), 3.39(4H, t, J=5.1Hz), 3.98(3H, s), 4.18(4H, t), 6.79(1H, m), 6.90(2H, m), 7.19(1H, m), 8.11(1H, s).	90-91°C
99		1.19(3H, t, J=7.5Hz), 2.39(3H, s), 2.58(2H, q, J=7.5Hz), 3.19(4H, t, J=5.0Hz), 3.96(3H, s), 4.09(4H, t, J=5.0Hz), 6.95(2H, m), 7.00(2H, m), 8.11(1H, s).	132-133°C
100	C <sub>22</sub> H <sub>30</sub> N <sub>4</sub> O <sub>3</sub> S <sub>1</sub> : theoretical. C, 61.37, H, 7.02, N, 13.01, S, 7.45 experimental. C, 61.47, H, 7.25, N, 13.21, S, 7.47	1.19(3H, t, J=7.5Hz), 2.40(3H, s), 2.58(2H, q, J=7.5Hz), 3.36(4H, t, J=4.5Hz), 3.75(6H, s), 3.96(3H, s), 4.13(4H, t), 6.09(3H, m), 8.13(1H, s).	166-167°C
101		1.20(3H, t, J=7.5Hz), 2.40(3H, s), 2.58(2H, q, J=8.0Hz), 3.37(4H, t), 3.96(3H, s), 4.15(4H, t), 6.98(2H, m), 7.46(1H, s), 8.13(1H, s).	163-164°C
102		1.18(3H, t, J=8.0Hz), 2.40(3H, s), 2.55(2H, q, J=7.5Hz), 3.11(4H, t), 3.75(2H, t), 3.87(2H, t), 3.89(3H, s), 3.97(3H, s), 6.86(1H, d), 6.94(2H, m), 7.04(1H, m), 7.26(1H, s).	89-90°C
103		1.26(3H, t, J=7.5Hz), 2.40(3H, s), 2.55(2H, q), 3.25(4H, t), 3.72(2H, t), 3.84(2H, t), 3.93(3H, s), 6.82(1H, d), 6.86(1H, d), 6.92(1H, s), 7.04(1H, s), 7.22(1H, m), 7.46(1H, s).	119-120°C
104	-	1.17(3H, t, J=7.5Hz), 2.39(3H, s), 2.53(2H, q, J=7.5Hz), 3.23(4H, t, J=5.0Hz), 3.64(2H, t), 3.79(6H, s), 3.79(2H, t), 5.96(1H, s), 6.12(2H, s), 7.30(1H, s).	oil phase

example number	elementary analysis	$^1\text{H}$ NMR (500MHz, $\text{CDCl}_3$ ) $\delta$	melting point
105	-	1.17(3H, t, J=7.5Hz), 2.42(3H, s), 2.56(2H, q, J=7.5Hz), 3.01(4H, t), 3.78(4H, t), 3.87(3H, s), 3.93(3H, s), 5.11(2H, s), 6.91(3H, m), 7.03(1H, m), 7.33(1H, s).	oil phase
106	-	1.15(3H, t, J=7.5Hz), 2.42(3H, s), 2.54(2H, q), 3.15(4H, t), 3.64(4H, t), 3.93(3H, s), 3.96(3H, s), 4.59(2H, s), 6.85(3H, m), 7.15(1H, s), 7.33(1H, s).	oil phase
107	-	2.19(3H, s), 2.34(3H, s), 3.26(4H, t), 3.69(4H, t), 3.97(3H, s), 6.82(1H, s), 6.94(3H, m), 7.30(2H, m), 8.14(1H, s).	140-141°C
108	$\text{C}_{20}\text{H}_{26}\text{N}_4\text{O}_3$ : theoretical, C, 64.85, H, 7.07, N, 15.12 experimental, C, 65.13, H, 7.24, N, 15.10	1.55(3H, s), 2.19(3H, s), 2.33(3H, s), 3.12(4H, t), 3.69(4H, t), 3.89(3H, s), 3.97(3H, s), 6.89(2H, m), 6.90(1H, s), 7.04(2H, m), 8.16(1H, s).	135-136°C
109	$\text{C}_{19}\text{H}_{23}\text{N}_4\text{O}_2\text{Cl}$ : theoretical, C, 60.88, H, 6.18, N, 14.95 experimental, C, 60.87, H, 6.28, N, 14.86	2.19(3H, s), 2.34(3H, s), 3.27(4H, t, J=5.2Hz), 3.66(4H, t, J=5.0Hz), 3.98(3H, s), 6.80(1H, d), 6.86(2H, m), 6.90(1H, s), 7.21(1H, m), 8.14(1H, s).	95-96°C
110	-	2.19(3H, s), 2.34(3H, s), 3.14(4H, t, J=4.9Hz), 3.68(4H, t, J=4.8Hz), 3.98(3H, s), 6.88(1H, s), 6.98(2H, m), 7.09(2H, m), 8.15(1H, s).	164-167°C
111	-	2.20(3H, s), 2.39(3H, s), 3.29(4H, t, J=5.0Hz), 3.67(4H, t, J=5.0Hz), 4.04(3H, s), 6.30(1H, m), 6.38(2H, d), 6.86(1H, s), 8.18(1H, s).	133-134°C
112	-	2.19(3H, s), 2.35(3H, s), 2.99(4H, t), 3.72(4H, t), 3.98(3H, s), 6.90(2H, m), 7.15(2H, m), 8.14(1H, s).	174-175°C

- 66 -

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
113		2.18(3H, s), 2.33(3H, s), 3.25(4H, t, J=5.0Hz), 3.67(4H, t, J=4.3Hz), 3.97(3H, s), 6.38(1H, d), 6.46(1H, s), 6.54(1H, d), 6.87(1H, s), 7.13(1H, t), 8.13(1H, s).	176-178°C
114		2.18(3H, s), 2.33(3H, s), 3.12(4H, t), 3.68(4H, t), 3.97(3H, s), 6.80(2H, m), 6.91(2H, m), 8.13(1H, s).	168-169°C
115		2.09(3H, s), 2.29(3H, s), 2.34(3H, s), 3.27(4H, t, J=5.0Hz), 3.67(4H, t, J=5.0Hz), 3.98(3H, s), 6.44(2H, m), 6.81(1H, m), 6.88(1H, s), 8.14(1H, s).	108-109°C
116		2.19(3H, s), 2.28(3H, s), 2.34(3H, s), 3.22(4H, t), 3.68(4H, t), 3.98(3H, s), 6.87(1H, s), 7.01(4H, m), 8.14(1H, s).	159-160°C
117		2.04(3H, s), 2.31(3H, s), 2.34(3H, s), 3.20(4H, t), 3.76(4H, t), 3.81(3H, s), 3.98(3H, s), 6.86(1H, s), 7.01(3H, m), 8.15(1H, s).	139-140°C
118	C <sub>21</sub> H <sub>22</sub> N <sub>4</sub> O <sub>4</sub> : theoretical, C, 62.98, H, 7.05, N, 13.99 experimental, C, 63.21, H, 7.19, N, 13.96	2.18(3H, s), 2.33(3H, s), 3.25(4H, t, J=5.0Hz), 3.67(4H, t), 3.80(6H, s), 3.97(3H, s), 6.07(3H, m), 6.86(1H, s), 8.14(1H, s).	150-151°C
119	C <sub>21</sub> H <sub>30</sub> N <sub>4</sub> O <sub>2</sub> : theoretical, C, 68.45, H, 7.66, N, 15.20 experimental, C, 68.26, H, 7.97, N, 14.99	2.19(3H, s), 2.26(3H, s), 2.28(3H, s), 2.34(3H, s), 2.94(4H, t), 3.66(4H, t), 3.97(3H, s), 6.89(3H, m), 8.33(1H, s).	134-135°C
120		2.16(3H, s), 2.29(6H, s), 2.33(3H, s), 3.23(4H, t), 3.66(4H, t), 3.97(3H, s), 6.53(3H, m), 6.87(1H, s), 8.14(1H, s).	125-126°C

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
121	-	2.19(3H, s), 2.26(3H, s), 2.34(3H, s), 2.95(4H, t, J=4.8Hz), 3.64(4H, t, J=4.8Hz), 3.78(3H, s), 3.97(3H, s), 6.57(1H, d), 6.58(1H, s), 7.11(1H, d), 8.32(1H, s).	127-130°C
122	-	2.19(3H, s), 2.30(3H, s), 2.42(3H, s), 2.94(4H, t), 3.69(4H, t), 3.97(3H, s), 6.69(1H, d), 6.82(1H, s), 6.88(1H, s), 7.04(1H, d), 8.14(1H, s).	184-185°C
123	-	2.04(3H, s), 2.33(3H, s), 3.15(4H, t), 3.67(4H, t), 3.89(3H, s), 3.97(3H, s), 6.65(1H, d), 6.81(1H, d), 8.14(1H, s).	172-176°C
124	-	2.20(3H, s), 2.48(3H, s), 3.17(4H, t), 3.76(4H, t), 4.00(3H, s), 6.94(1H, s), 7.11(1H, d), 7.40(1H, m), 7.50(1H, m), 7.61(1H, d), 8.19(1H, s).	202-204°C
125	-	2.21(3H, s), 2.44(3H, s), 3.04(4H, t), 3.77(4H, t), 4.05(3H, s), 6.97(1H, m), 7.49(4H, m), 8.01(2H, m), 8.27(1H, m), 8.43(1H, s).	103-104°C
126	-	2.22(3H, s), 2.43(3H, s), 3.39(4H, t, J=5.0Hz), 4.02(3H, s), 4.17(4H, t), 6.87(1H, d), 6.91(1H, d), 6.96(1H, s), 7.24(2H, m), 8.12(1H, s).	168-169°C
127	-	2.21(3H, s), 2.42(3H, s), 3.38(4H, t, J=5.0Hz), 4.02(3H, s), 4.17(4H, t), 6.87(1H, s), 6.91(2H, d), 6.96(1H, s), 8.12(1H, s).	oil phase
128	C <sub>20</sub> H <sub>26</sub> N <sub>4</sub> O <sub>2</sub> S <sub>1</sub> : theore- C, 62.15, H, 6.78, tical. N, 14.50, S, 8.29 experi- C, 62.60, H, 7.19, mental. N, 14.70, S, 8.48	2.17(3H, s), 2.36(3H, s), 3.30(4H, t), 3.19(3H, s), 3.96(3H, s), 4.21(4H, t), 6.95(4H, m), 8.03(1H, s).	160-161°C

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
129		2.21(3H, s), 2.36(3H, s), 3.37(4H, t), 3.79(6H, s), 3.96(3H, s), 4.10(4H, t), 6.10(2H, m), 7.46(1H, s), 8.10(1H, s).	166-167°C
130	-	2.11(2H, m), 2.87(4H, m), 3.12(4H, t, J=4.95Hz), 3.70(4H, t, J=4.8Hz), 3.89(3H, s), 4.00(3H, s), 6.89(2H, m), 7.05(2H, m), 8.26(1H, s).	130-131°C
131		2.12(2H, m), 2.87(4H, m), 3.27(4H, t, J=5.0Hz), 3.67(4H, t, J=5.0Hz), 4.00(3H, s), 6.80(1H, m), 6.90(2H, m), 7.21(1H, m), 8.23(1H, s).	142-146°C
132		2.12(2H, m), 2.87(4H, m), 3.27(4H, t, J=5.0Hz), 3.68(4H, t, J=5.0Hz), 4.00(3H, s), 6.97(3H, m), 7.07(1H, m), 8.24(1H, s).	152-153°C
133		1.76(2H, m), 1.83(2H, m), 2.68(2H, t, J=5.7Hz), 2.72(2H, t, J=5.9Hz), 3.13(4H, t), 3.71(4H, t), 3.89(3H, s), 3.97(3H, s), 6.95(4H, m), 8.09(1H, s).	oil phase
134		1.75(2H, m), 1.83(2H, m), 2.68(2H, t, J=6.1Hz), 2.75(2H, t, J=6.0Hz), 3.27(4H, t, J=5.15Hz), 3.67(4H, t, J=4.9Hz), 4.00(3H, s), 6.81(1H, d), 6.90(2H, m), 7.20(1H, m), 8.08(1H, s).	oil phase
135		1.76(2H, m), 1.84(2H, m), 2.68(2H, t), 2.72(2H, t), 3.14(4H, t, J=5.0Hz), 3.68(4H, t, J=5.0Hz), 3.97(1H, s), 6.99(1H, s), 7.00(2H, m), 7.09(2H, m), 8.08(1H, s).	134-135°C
136		0.90(3H, s), 0.91(3H, s), 2.07(2H, m), 2.48(3H, d), 3.22(4H, t), 3.80(4H, t), 3.88(3H, s), 3.99(3H, s), 6.67(1H, d), 6.94(1H, s), 6.98(3H, m), 8.24(1H, s).	oil phase

- 69 -

example number	elementary analysis	<sup>1</sup> H NMR (500MHz, CDCl <sub>3</sub> ) δ	melting point
137	-	0.90(3H, s), 0.91(3H, s), 2.07(1H, m), 2.49(3H, d), 3.29(3H, t, J=5.0Hz), 3.74(4H, t, J=4.8Hz), 4.00(3H, s), 6.69(1H, m), 6.89(2H, m), 7.21(1H, m), 8.24(1H, m).	oil phase
138		0.91(3H, s), 0.92(3H, s), 2.08(1H, m), 2.54(3H, d), 3.32(4H, t), 3.95(4H, t), 4.20(3H, s), 6.70(1H, d), 6.93(1H, s), 7.14(3H, m), 8.26(1H, s).	oil phase
139		3.03(4H, t), 3.69(4H, t), 3.78(3H, s), 4.02(3H, s), 6.89(4H, m), 7.04(1H, s), 7.77(1H, dd), 8.40(1H, dd).	168-169°C
140		3.13(4H, t), 3.71(4H, t), 3.89(3H, s), 4.02(3H, s), 6.84(4H, m), 6.91(1H, m), 7.05(1H, m), 7.78(1H, m), 8.42(1H, m).	173-174°C
141		3.27(3H, t, J=5.0Hz), 3.69(4H, t), 4.03(3H, s), 6.89(1H, m), 7.04(1H, s), 7.32(2H, m), 7.78(1H, dd), 8.40(1H, dd).	133-135°C
142		3.28(4H, t, J=5.2Hz), 3.69(4H, t, J=5.0Hz), 4.03(3H, s), 6.83(1H, m), 6.90(3H, m), 7.20(1H, m), 7.79(1H, m), 8.40(1H, m).	95-96°C
143		1.17(3H, t, J=7.5Hz), 2.37(3H, s), 2.54(2H, q), 3.17(4H, t, J=3.2Hz), 3.66(4H, t), 3.98(3H, s), 4.56(1H, s), 6.93(1H, s), 7.00(2H, m), 8.19(1H, s).	225-227°C
144		1.16(3H, t, J=7.5Hz), 2.40(3H, s), 2.54(2H, q, J=7.5Hz), 3.07(4H, t), 3.49(4H, t), 3.95(3H, s), 4.34(2H, d), 4.53(1H, s), 6.97(2H, m), 7.32(1H, s), 7.79(1H, s).	143-145°C

example number	elementary analysis	$^1\text{H}$ NMR (500MHz, $\text{CDCl}_3$ ) $\delta$	melting point
145		1.11(3H, t, J=7.5Hz), 2.30(3H, s), 2.42(2H, q), 3.04(4H, t), 3.48(4H, t), 4.06(2H, d), 4.28(2H, d), 4.36(1H, s), 6.97(2H, m), 7.34(1H, s), 7.84(1H, s).	oil phase
146		1.22(3H, t), 2.29(3H, s), 2.37(2H, q), 3.13(4H, t), 3.41(4H, t), 3.56(2H, d), 4.27(4H, s), 6.90(3H, m), 7.04(5H, s), 7.25(5H, s).	oil phase
147		0.91(3H, s), 1.02(3H, s), 1.28(3H, t), 2.48(3H, s), 3.04(4H, t), 3.54(4H, t), 4.36(2H, q), 5.98(2H, d), 6.90(3H, m), 7.68(1H, s).	oil phase
148		1.14(3H, t, J=7.5Hz), 2.35(3H, s), 2.43(2H, q, J=7.5Hz), 3.51(4H, t, J=4.6Hz), 3.90(4H, t, J=4.6Hz), 3.92(3H, s), 6.19(1H, d), 7.21(2H, dd), 7.65(1H, m), 7.78(1H, s).	158-159°C
149		1.09(3H, t, J=7.5Hz), 2.38(3H, s), 2.54(2H, q, J=7.5Hz), 3.31(4H, t, J=5.0Hz), 3.63(4H, t, J=5.0Hz), 3.92(3H, s), 6.84(1H, d), 6.96(2H, dd), 7.21(1H, d), 7.69(1H, s).	198-199°C



- 71 -

Antitumor activities of the compounds of present invention were tested. Antitumor activities of compounds of the present invention were tested in vitro against 5 kinds of human tumor cell lines and 2 kinds of leukemia tumor cell lines. The method of in vitro test is as follows.

5

Example 1)

In vitro antitumor effect against human tumor cell lines

A. Tumor cell line : A549 (human non-small lung cell)

SKOV-3 (human ovarian)

10

HCT-15 (human colon)

XT 498 (human CNS)

SKMEL 2 (human melanoma)

B. Method of test(SRB Assay Method)

15 a. Human solid tumor cell lines, A594(non-small lung cell), SKMEL-2(melanoma), HCT-15(colon), SKOV-3(ovarian), XF-498(CNS) were cultured at 37°C, in 5% CO<sub>2</sub> incubator using the RPMI 1640 media containing 10% FBS, while they were transfer-cultured successively once or twice per week. Cell cultures were dissolved into the solution of 0.25% trypsin and 3 mM CDTA PBS(-) and then cells were separated from media  
20 which the cells were stucked on.

b.  $5 \times 10^3$ - $2 \times 10^4$  cells were added into each well of 96-well plate and cultured in 5% CO<sub>2</sub> incubator, at 37°C, for 24 hours.

25 c. Each sample drugs was dissolved in a small quantity of DMSO, and diluted to concentrations prescribed in experiment with media, and then the final concentration of DMSO was controlled below 0.5%.

d. A medium of each well cultured for 24 hours as above b., was removed by aspiration. 200  $\mu$ l of drug samples prepared in c. was added into each well and the wells were cultured for 48 hours. Tz(time zero) plates were collected at the point of time drugs were added.

30 e. After Tz plates and plates were treated with cell fixing by TCA of SRB assay method, staining of 0.4% SRB solution, washing with 1% acetic acid, OD values were measured at 520 nm, following elution of dye with 10 mM Tris solution.

35 C. Calculation of result

a. Time zero(Tz) value was determined by obtainment of SRB protein value at the point of time drugs were added.

- 72 -

b. Control value(C) was determined with OD value of well that was not added with drug.

c. Drug-treated test value(T) was determined with OD value of well treated with drug.

5 d. Drug effects of growth stimulation, net growth inhibition, net killing etc. were determined with Tz, C and T.

e. If  $T \geq T_z$ , cellular response function was calculated with  $100 \times (T - T_z) / (C - T_z)$ , and if  $T < T_z$ , with  $100 \times (T - T_z) / T_z$ .

The results are shown in the next table.

10

#### \* REFERENCE

- 1) P. Skehan, R. Strong, D Scudiero, A. Monks, J. B.Mcmahan, D.T. Vistica, J. Warren, H. Bokesch, S. Kenny and M. R. Boyd : Proc. Am. Assoc. Cancer Res., 30, 612(1989)
- 15 2) L.V. Rubinstein, R.H. Shoemaker, K. D. Paull, R.M. simon, S. Tosini, P. Skehan, D. Scudiero, A. Monks and M. R. boyd. ; J. Natl. Cancer Inst., 82, 1113(1990)
- 3) P. Skehan, r. strong, D. Scudiero, A. monks, J. B. Memahan, D. t. Vistica, J. Warren, H. Bokesch, S. Kenny and M. R. Boyd.; J. Natl. Cancer ins., 82, 1107(1990)
- 20

#### D. Results.

It was found that the compounds of present invention have the superior antitumor activities to those of the control, cisplatin against 5 kinds of human  
 25 solid cancer cell lines. Especially, compounds of example 1), 6), 13), 16), 28), 29), 38), 41), 47), 48), 49), 50), 55), 61), 91), 97), 98), 100), 108), 109), 111), 113), 115), 118), 119), 120), 121), 126), 128), 129), 144), 148), 149) have superior antitumor activities to those of cisplatin.

30

35

EXAMPLE NUMBER	NET GROWTH AS% OF CONTROL (Conc. $\mu\text{g/mL}$ )				
	A594	SK-OV-3	SK-MEL-2	XF-498	HCT-15
1	0.1372	0.0269	0.0172	0.1149	0.0479
6	0.0091	0.0072	0.0092	0.0156	0.0108
8	1.1428	0.3930	0.8302	1.2938	1.0499
13	0.2483	0.0697	0.1771	0.2769	0.0829
16	0.4491	0.0263	0.0182	0.1662	0.1160
18	1.0813	0.7207	0.8138	0.8275	0.6850
21	1.9952	1.0423	1.7609	2.8475	0.6684
22	2.2086	1.2588	1.8210	2.3352	0.6764
23	1.9836	0.5929	0.8665	2.2896	1.0053
28	0.5958	0.3192	0.6495	0.7663	0.3756
29	0.0002453	0.0001310	0.0007708	0.0001901	0.0007707
38	0.4266	0.0709	0.0833	0.2836	0.0652
41	0.4464	0.0836	0.0981	0.3818	0.0878
47	0.3693	0.2094	0.4384	0.4998	0.2975
48	0.0913	0.0583	0.0954	0.1430	0.0498
49	0.0917	0.0223	0.0723	0.0955	0.0946
50	0.0984	0.0732	0.0954	0.0736	0.0828
55	0.5074	0.1088	0.2812	0.4094	0.1577
60	2.8176	1.7486	0.6468	2.1795	0.3410
61	0.8539	-0.1710	0.1594	0.4343	0.0910

- 74 -

EXAMPLE NUMBER	NET GROWTH AS% OF CONTROL (Conc. $\mu\text{g/mL}$ )				
	A594	SK-OV-3	SK-MEL-2	XF-498	HCT-15
62	3.5875	0.2431	0.2894	1.1457	0.2950
91	0.5284	0.3156	0.5562	0.9176	0.5979
97	0.3518	0.0536	0.01778	0.2965	0.1489
98	0.3489	0.0645	0.1822	0.2229	0.1801
100	0.0016111	0.0015197	0.0032233	0.0020713	0.0065666
108	0.1158	0.0797	0.1277	0.1352	0.0741
109	0.1088	0.0832	0.1079	0.1494	0.0581
111	0.1611	0.0661	0.1258	0.0949	0.0749
113	0.4371	0.1680	0.3368	0.5967	0.0973
115	0.6168	0.2201	0.3672	1.4025	0.2081
118	0.0038	0.0011	0.0046	0.0042	0.0024
119	0.3824	0.1129	0.2414	0.5133	0.2026
120	0.0001299	0.0000226	0.0002677	0.0001193	0.0001265
121	0.0116039	0.0020599	0.0177227	0.0087927	0.0070088
126	0.006171	0.0005225	0.0110493	0.0048476	0.0058752
127	1.5462	0.4162	0.4776	1.3486	0.5366
128	0.0059411	0.0013953	0.0127665	0.0039702	0.0065951
129	0.0000119	0.0000033	0.0000389	0.0000117	0.0000384
144	1.0350	0.6289	0.6060	4.4550	0.4738
148	0.6767	0.3129	0.1582	0.7615	0.3203
149	0.3883	0.1819	0.1731	0.4255	0.0471
Cisplatin	0.8184	0.7134	0.7147	0.7771	3.0381

### Example 2)

\* In vitro antitumor effects against animal leukemia cells.

### A. Material of experiment

Tumor cell lines : L1210(mouse leukemia cell)

5 - P388 (mouse lymphoid neoplasma cell)

### B. Method of experiment(Dye Exclusion Assay)

1) L1210 and P388 cells that were cultured in RPMI 1640 media containing 10 % FBS were regulated as the cell concentration of  $1 \times 10^6$  cells/ml.

2) Sample drugs diluted with log dose were added into the cells, and it were cultured at 37°C, for 48 hours, in 50 % CO<sub>2</sub> incubator, and then viable cell number was measured, Viable cell number was measured with dye exclusion test using trypan blue.

3) The concentration of sample compounds of 50 % cell growth inhibition compared with standard group was determined as IC<sub>50</sub>. The results are shown at the next table.

### \* REFERENCE

1) P.Skehan, R. Strong, D. Scudiero, A. Monks, J. B. McMahon, D. T. Vistica,  
J. Warren, H. Bokesh, s. Kenney and M. R. Boyd. : Proc. Am. Assoc.  
20 Cancer  
Res., 30, 612(1989).

2) L.V.Rubinstein, R.H.Shoemaker, K.D Paull, R.M. Simon, S.  
Tosini,P.Skehan,

D. Scudiero, A. Monks, J. Natl. Cancer Inst., 82, 1113(1990)

25 3) P.Skehan, R. Strong, D.Scudiero, J. B. Mcmanhan, D.T. Vistica, J. Warren.

H. Bokesch, S.Kenney and M.R. Boyd. : J. Natl. Cancer Inst., 82, 1107(1990)

## 30 C. Result

As the results of measurement of antitumor activities of compounds of the present invention against L1210 and P388 mouse cancer cells, it was found that compounds of example 1), 6), 13), 16), 29), 38), 41), 47), 48), 49), 108), 118), 120), 128), 148), 149) had same or more excellent antitumor activities than those of the control drug, mytomicin C.

- 76 -

EXAMPLE NUMBER	ED <sub>50</sub> (μg/mL)	
	L1210	P388
1	1.6	0.6
6	0.6	0.3
13	1.7	1.6
16	1.8	1.6
29	0.4	0.5
38	1.4	1.0
41	1.4	2.0
47	0.3	0.3
48	1.9	1.8
49	1.3	0.6
50	2.0	1.5
97	2.0	1.6
98	2.0	2.1

- 77 -

EXAMPLE NUMBER	ED <sub>50</sub> ( $\mu\text{g/mL}$ )	
	L1210	P388
108	- 0.8	0.9
118	0.06	0.06
119	2.2	2.0
120	0.3	0.1
128	0.5	0.2
148	1.5	1.3
149	0.9	1.6
mitomycin C	1.6	1.1

In vivo antitumor activity test was carried out in mice with samples having significance in in vitro test.

5 Example 3)

\* In vivo antitumor effects against mouse leukemia P388 cells.

A. Material of experiment

BDFI mice were used.

B. Method of experiment

10 1) Leukemia P388 cells being transfer-cultured successively in DBA/2 mouse, were grafted i.p. into each mouse of a group comprising 8 mice of 6 week old BDFI mouse as the dose of  $1 \times 10^6$  cells/ 0.1 ml.

2) Sample drugs were dissolved in PBS or suspended in 0.5% Tween 80, and then injected into abdominal cavity of mouse at each prescribed  
15 concentration on days 1, 5, 9, respectively.

3) With observation every day, survival times of tested mice were measured. Antitumor activities was determined in such a manner that the increasing ratio(T/C%) of average survival days of drug-treated groups compared with the control group was calculated using the mean survival  
20 times of each tested groups.

The results are shown at the next table.

\* REFERENCE

25 A. Goldin, J. M. Venditti, J. S. Macdonald, F.M.Muggia, J.E.Henney and V. T. DeVita. :Euro. J. S. Macdonald, F. M. Muggia, J. E. Henney and V. T.

DeVita: Euro. J. Cancer, 17, 129 (1981).

30 \* Experimental Conditions for mouse P388

Animal	: BDFI mouse ( 8 mice/ group )
Tumor	: mouse P388
Inoculum size	: $10^6$ cells/mouse
Inoculum site	: i. p.
35 Treatment site	: i. p.
Treatment time	: days 1, 5, 9
Parameter	: median survival time
Criteria	: T/C %



- 79 -

## C. Result

Through in vivo experiment using P388 mouse cancer cells, significant antitumor effect of the compounds of example 1), 6), 16), 29) were observed.

Example No.	Dose (mg/kg)	T/C(%)	etc.
1	100	134.6	
	50	109.1	
6	100	183.3	
	50	133.3	
16	100	131.8	
	50	113.6	
29	100	190.9	
	50	136.4	

## Example 4)

\* In vivo antitumor activities against mouse solid tumor, B16 melanoma.

## A. Material of experiment.

BDF1 mouse was used in experiment while being successively transfer-cultured in C57BL/6 mice by s.c.

## B. Methods

1) After 1g of tumor was added into cold balanced salt solution up to be 10ml, it was homogenized (10:1, brei).

2) 0.5 ml Brei of the above 1) were grafted into each BDF1 mouse by i. p.

3) Median survival time was measured, and the activity was determined in such a manner that if T/C was over 125 %, it presented moderate activity, while if it is over 150. %, it had significant activity.

The results are shown at the next table.

## \*REFERENCE

A. Goldin, J. M. Venditti, J. S. Macdonald, F. M. Muggia, J.E.Henney and V. T. DeVita, Euro.J.Cancer, 17, 129(1981).

## \* Experimental Conditions for Mouse B16 melanoma.

5

Animal	:BDFI mouse ( 8 mice /group)
Inoculum size	: $10^5$ cells/mouse
Inoculum site	:i. p.
Treatment site	:i. p.
10 Treatment time	:days 1, 5, 9
Parameter	:median survival time
Criteria	:T/C %

## C. Results

15

With in vivo experiment using B16 mouse melanoma solid tumor, it was observed that the compounds of examples 6), 16) etc. have the significant antitumor activities.

20

25

Example No.	Dose	T/C(%)	Etc.
6	200	139.4	
	100	124.2	
	50	127.3	
16	200	118.2	
	100	127.3	
	50	115.2	

30

## Example 5)

\* Acute toxicity test (  $LD_{50}$  ) : Litchfield-Wilcoxon method.

6 week old ICR mice(male  $30 \pm 2.0g$ ) was fed freely with solid feed and water at room temperature,  $23 \pm 1^\circ C$  and at humidity  $60 \pm 5\%$ . Sample drugs were injected into the abdominal cavities of mice, while each group comprises 6 mice.

35

Observed during 14 days, external appearances and life or dead were recorded, and then, visible pathogenies were observed from dead animals by dissection.  $LD_{50}$  value was calculated by Litchfield-wilcoxon method.

- 81 -

The results are shown at the next table.

Example No.	LD <sub>50</sub> (mg/ml)	
	i.p.	p.o.
6	248.5	>622
5 28	>1,800	>2,000
61	>1,687	
97	1,100	
98	>1,800	>2,000
10 108	>2,000	>3,110
109	2,000	>2,073
118	182.8	571.8
148	425.3	
15 149	410.5	
cisplatin	21.4	

As described above, it was found that the compounds of the present invention are more safer and have superior antitumor activities to cisplatin, and accordingly have solved the problems of drugs by the prior art such as restriction of dosage, toxicity, etc.

#### Examples of pharmaceutical preparations

Tablets: (examples 1-4)

25 Tablet(250mg) was prepared with the ingredients of the following table by conventional tablet manufacturing method.

Examples	ingredients(mg)	
1	compound of example 1	20
30	lactose	120
	microcrystalline cellulose	30
	corn starch	40
	povidone	30
	sodium starch glycolate	8
35	magnesium stearate	2
2	compound of example 148	20

- 82 -

5		lactose	110
		microcrystalline cellulose	40
		corn starch	45
		povidone	25
		sodium starch glycolate	8
		magnesium stearate	2
10	3	compound of example 16	20
		lactose	120
		microcrystalline cellulose	35
		corn starch	35
		povidone	30
		sodium starch glycolate	8
15		magnesium stearate	2
20	4	compound of example 149	20
		lactose	100
		microcrystalline cellulose	45
		corn starch	50
		povidone	25
		sodium starch glycolate	8
		magnesium stearate	2

# 25 Capsules(example 5-8)

Capsule(250mg) was prepared with the ingredients of the following table by conventional capsule manufacturing method.

Examples		ingredients(mg)	
30	5	compound of example 1	10
		lactose	100
		corn starch	100
		povidone	30
		sodium starch glycolate	7
		magnesium stearate	3
35	6	compound of example 148	10
		lactose	105

- 83 -

		corn starch	100
		povidone	25
		sodium starch glycolate	7
		magnesium stearate	3
5		-	
	7	compound of example 16	10
		lactose	90
		corn starch	110
		povidone	30
10		sodium starch glycolate	7
		magnesium stearate	3
	8	compound of example 149	10
		lactose	95
15		corn starch	110
		povidone	25
		sodium starch glycolate	7
		magnesium stearate	3
20	Injectable preparations (examples 9 - 16)		
	Injectable preparations( 5ml of ampoule and vial) were prepared with the ingredients of the following tables by the conventional injection manufacturing method.		
25	Examples (ampoule) ingredients		
	9	compound of example 1	30mg
		polyoxy 35 castor oil	4000mg
		absolute ethanol	1.17ml
		distilled water for inj.	q.s.
30		-	
	10	compound of example 148	30mg
		polyoxy 35 castor oil	3200mg
		absolute ethanol	1.97ml
		distilled water for inj.	q.s.
35		-	
	11	compound of example 16	30mg
		polyoxy 35 castor oil	3500mg

- 84 -

		absolute ethanol	1.68ml
		distilled water for inj.	q.s.
5	12	compound of example 149	30mg
	-	polyoxy 35 castor oil	3000mg
		absolute ethanol	2.16ml
		distilled water for inj.	q.s.
10	Example 13(vial)	compound of example 1	30mg
		polyoxy 35 castor oil	4000mg
		absolute ethanol	1.17ml
		distilled water for inj.	q.s.
15	14	compound of example 148	30mg
		polyoxy 35 castor oil	3200mg
		absolute ethanol	1.97ml
		distilled water for inj.	q.s.
20	15	compound of example 16	30mg
		polyoxy 35 castor oil	3500mg
		absolute ethanol	1.68ml
		distilled water for inj.	q.s.
25	16	compound of example 149	30mg
		polyoxy 35 castor oil	3000mg
		absolute ethanol	2.16ml
		distilled water for inj.	q.s.

## Ointment(examples 17 - 20)

30 Ointment(1g) was prepared with the ingredients of the following table by the conventional ointment manufacturing method.

Examples	ingredients(mg)	
35	17	compound of example 1
		6
		polyoxy 40 hydrogenated castor oil
		350
		absolute ethanol
		100
		sodium p-oxybenzoate
		1.5

- 85 -

		NaH <sub>2</sub> PO <sub>4</sub>	1.06
		citric acid	1.48
		propyleneglycol	200
5		glycerine	150
		cetostearyl alcohol	50
		cetiol H. E.	130
		purified water	q.s.
	18	compound of example 148	6
10		polyoxy 40 hydrogenated castor oil	300
		absolute ethanol	100
		sodium p-oxybenzoate	1.5
		NaH <sub>2</sub> PO <sub>4</sub>	1.06
		citric acid	1.48
15		propyleneglycol	200
		glycerine	150
		cetostearyl alcohol	50
		cetiol H. E.	145
		purified water	q.s.
20			
	19	compound of example 16	6
		polyoxy 40 hydrogenated castor oil	350
		absolute ethanol	150
		sodium p-oxybenzoate	1.5
25		NaH <sub>2</sub> PO <sub>4</sub>	1.06
		citric acid	1.48
		propyleneglycol	150
		glycerine	150
		cetostearyl alcohol	100
30		cetiol H. E.	135
		purified water	q.s.
	20	compound of example 149	6
35		polyoxy 40 hydrogenated castor oil	300
		absolute ethanol	100
		sodium p oxybenzoate	1.5
		NaH <sub>2</sub> PO <sub>4</sub>	1.06

- 86 -

	citric acid	1.48
	propyleneglycol	200
5	glycerine	100
	cetostearyl alcohol	100
	- cetiol H. E.	147
	purified water	q.s.

## Suppository(examples 21-24)

10      Suppository(1g) was prepared with the ingredients of the following table by conventional suppository manufacturing method.

Example	ingredients(mg)	
15	21	compound of example 1      6
		polyoxy 35 castor oil      250
		glycerine      80
		propyleneglycol      50
		stearyl alcohol      50
20		stearic acid      50
		Witepsol <sup>®</sup> 364
		glycerylmonostearate      150
25	22	compound of example 148      6
		polyoxy 35 castor oil      230
		glycerine      80
		propyleneglycol      70
		stearyl alcohol      50
		stearic acid      50
30		Witepsol <sup>®</sup> 414
		glycerylmonostearate      100
35	23	compound of example 16      6
		polyoxy 35 castor oil      245
		glycerine      80
		propyleneglycol      65
		stearyl alcohol      70
		stearic acid      60
		Witepsol <sup>®</sup> 394



- 87 -

		glycerylmonostearate	80
5	24	compound of example 149	6
		polyoxy 35 castor oil	225
		glycerine	70
		propyleneglycol	60
		stearyl alcohol	55
		stearic acid	50
10		Witepsol <sup>®</sup>	459
		glycerylmonostearate	75

Oral solution(example 25-28)

15 Oral solution(100ml) was prepared with the ingredients of the following tables by the conventional oral solution manufacturing method.

Example	ingredients	
20	25	compound of example 1 30mg
		polyoxy 40 hydrogenated castor oil 30g
		absolute ethanol 2ml
		propyleneglycol 15g
		polyethyleneglycol 400 10g
		Tween 80 5g
25		methy p-oxybenzoate 0.1g
		purified sugar 12g
		herb perfume 0.1mg
		purified water q.s.
30	26	compound of example 148 30mg
		polyoxy 35 castor oil 30g
		absolute ethanol 2ml
		propyleneglycol 12g
		polyethyleneglycol 15g
35		Tween 80 10g
		methyl p-oxybenzoate 0.1g
		purified sugar 12g
		herb perfume 0.1ml
		purified water q.s.

- 88 -

5	27	compound of example 16	30mg
		polyoxy 35 castor oil	25g
		absolute ethanol	2ml
		propyleneglycol	20g
		polyethyleneglycol 400	15g
		Tween 80	7g
		methyl p-oxybenzoate	0.1g
		purified sugar	15g
	10	herb perfume	0.15ml
		purified water	q.s.
15	28	compound of example 149	30mg
		polyoxy 35 castor oil	30g
		absolute ethanol	2ml
		propyleneglycol	17g
		polyethyleneglycol 400	12g
		Tween 80	10g
		methyl p-oxybenzoate	0.1g
	20	purified sugar	13g
		herb perfume	0.15ml
		purified water	q.s.

## Troche(examples 29-32)

25 Troche(500mg) was prepared with the ingredients of the following table by conventional troche manufacturing method.

Example	ingredients(mg)	
30	29	compound of example 1 20
		mannitol 300
		sugar 100
		corn starch 40
		povidone 30
		sodium starch glycolate 8
	35	magnesium stearate 2
30		compound of example 148 20

- 89 -

		mannitol	280
		sugar	120
		corn starch	45
		povidone	25
5		sodium starch glycolate	8
		magnesium stearate	2
	31	compound of example 16	20
		mannitol	320
10		sugar	100
		corn starch	20
		povidone	30
		sodium starch glycolate	8
		magnesium stearate	2
15			
	32	compound of example 149	20
		mannitol	300
		sugar	110
		corn starch	50
20		povidone	10
		sodium starch glycolate	8
		magnesium stearate	2
25			
30			
35			


- 90 -

What is claimed is :

1. A compound of the general formula(I) and pharmaceutically acceptable acid addition salt thereof.

5

10



(I)

15


wherein R<sub>1</sub> and R<sub>2</sub> are independently hydrogen, C<sub>1</sub>-C<sub>6</sub> alkyl or optionally substituted C<sub>3</sub>-C<sub>6</sub> membered cycloalkyl containing C<sub>2</sub>-C<sub>6</sub>; R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub> and R<sub>7</sub> are independently hydrogen, halogen, hydroxy, nitro, C<sub>1</sub>-C<sub>4</sub> lower ester, C<sub>1</sub>-C<sub>4</sub> lower alkyl, C<sub>1</sub>-C<sub>4</sub> lower alkoxy, aryl, arylalkoxy or unsaturated amine; l is an integer of 0-7; m and n are independently an integer of 0-1; W is carbon or nitrogen; X is oxygen, sulfur, optionally substituted imine; Y is nitrogen or oxygen; and Z is hydrogen, C<sub>1</sub>-C<sub>6</sub> alkoxy, aryloxy, C<sub>1</sub>-C<sub>4</sub> alkylamine, cycloamine containing N<sub>1</sub>-N<sub>3</sub> or oxo group.

20

2. A compound of the general formula (I') as claimed in claim 1, wherein Z is oxo group.

25

30



(I')


35 wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, l, m, n, W, X and Y are the same with those in the claim 1 and pharmaceutically acceptable acid addition thereof.

3. A pharmaceutical composition comprising a compound of the general

- 91 -

formula (I) or acid addition salt thereof as active ingredient and one or more conventional adjuvants selected from the group consisting of conventional vehicles, binding agent, degrading agent, lubricating agent, dissolving agent, aids for dissolution, stabilizing agent, base of ointment, pH-adjusting agent, perfume or the like.

10



(I)

wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub>, R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, l, m, n, W, X, Y and Z are the same with those in the claim 1.

20

25

30

35

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 96/00005

## A. CLASSIFICATION OF SUBJECT MATTER

IPC<sup>6</sup>: C 07 D 213/65, 213/32, 213/14; A 61 K 31/44

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>6</sup>: C 07 D 213/00; A 61 K 31/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  
AT, Chemical Abstracts

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Questel DARC, CAS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 547 517 A1 (THOMAE) 23 June 1993 (23.06.93), claims 1,8-12.	1-3
A	US 5 196 428 A (MEANWELL) 23 March 1993 (23.03.93), claims 1,21,22; examples 12,17-19,25.	1-3
A	WO 87/07 895 A1 (UPJOHN) 30 December 1987 (30.12.87), claims 1 D (5) F-28.	1-3
A	DE 24 23 650 A (RHONE) 05 December 1974 (05.12.74), claim 1(1).	1-3
A	EP 0 2 77 725 A2 (ROBINS) 10 August 1988 (10.08.88), claim 1; table 1, example 38.	1-3
A	Chemical Abstracts, Vol.115, No.23, 09 December 1991 (Columbus, Ohio, USA), page 873, column 1, abstract No. 256226a, SHIBUYA, M. et al.: "Preparation of piperazine derivatives as antiarrhythmics", Jpn. Kokai Tokkyo Koho JP 03,141,258.	1,3

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 March 1996 (22.03.96)

Date of mailing of the international search report

03 May 1996 (03.05.96)

Name and mailing address of the ISA/ AT  
AUSTRIAN PATENT OFFICE  
Kohlmarkt 8-10  
A-1014 Vienna  
Facsimile No. 1/53424/535

Authorized officer

Hammer

Telephone No. 1/5337058/44

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/KR 96/00005

**C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Chemical Abstracts, Vol.113, No.3, 16 July 1990 (Columbus, Ohio, USA), page 17, column 2, abstract No. 17483j, WALSH, D.A. et al.: "Synthesis and antiallergy activity of N-[2-(dimethylamino)ethyl]-4-aryl-1-piperazinecarboxamide-derivatives", J. Med. Chem. 1990, 33(7), 2028-32 (Eng).	1,3
A	Chemical Abstracts, Vol.92, No.4, 28 January 1980 (Columbus, Ohio, USA), page 359, column 1, abstract No.27816g, HARDY, H.L. et al.: "Novel reagent for the determination of atmospheric isocyanate monomer concentrations", Analyst (London) 1979, 10(1242), 890-1 (Eng).	1
A	Chemical Abstracts, Vol.119, No.25, 20 December 1993 (Columbus, Ohio, USA), page 993, column 2, abstract No.271117s, MEANWELL, N.A. et al.: "Inhibitors of blood platelet cAMP phosphodiesterase. 4. Structural variation of the side-chain terminus of water-soluble 1,3-dihydro-2H-imidazo[4,5-b]quinolin-2-one derivatives", J. Med. Chem. 1993, 36(22), 3251-64 (Eng).	1,2
	-----	

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.

PCT/KR 96/00005

In Recherchenbericht angeführtes Patentdokument Patent document cited in search report Document de brevet cité dans le rapport de recherche		Datum der Veröffentlichung Publication date Date de publication	Mitglied(er) der Patentfamilie Patent family member(s) Membre(s) de la famille de brevets	Datum der Veröffentlichung Publication date Date de publication
EP A1	547517	23-06-93	AT E 122658 AU A1 300587/93 AU B2 655345/93 CA AA 20050001 DE A1 43316822/93 DE CO 59330322/93 DE B1 90447511/93 FI AO 90323256/93 FI A 90323256/93 HU AO 90323256/93 HU A2 68000000 IL AO 10400666 JP A2 61997999 NZ A 224544/93 FL A1 22968896/93 US A1 54402294/93 DE A1 42164464/93 NO AO 90323256/93 NO A 90323256/93 DE A1 41413777/93 ZA A 22009611/93 AU A1 29817799/93 AU B2 661155/93 CA AA 90323256/93 CZ A 90323256/93 EP A1 90323256/93 FI AO 90323256/93 FI A 90323256/93 HU A2 677144/93 IL AO 10336755 NO AO 60000666/93 NO A 90323256/93 NZ A 90323256/93 ZA A 90323256/93 US A 53875999/93 US A 54788228	15-06-93 17-06-93 29-09-93 15-06-93 15-11-93 15-06-93 17-06-93 14-12-93 15-06-93 15-06-93 15-06-93 13-06-93 19-06-93 09-06-93 09-06-93 11-06-93 11-06-93 11-06-93 13-06-93 17-06-93 17-06-93 27-07-93 14-08-93 15-08-93 16-08-93 09-09-93 14-09-93 04-10-93 22-10-93 11-11-93 14-11-93 21-11-93 07-12-93 26-12-93
US A	5196428	23-03-93	keine - none - rien	
WO A1	8707895	30-12-87	AU A1 75801/87	12-01-88
DE A	2423650		AR A1 209421 AR A1 2110851 AT A 866776 AT A 4008774 AT E 3326000 AT E 3326001 AU A1 68880774 CA A1 10132971 CH A 90323256/93 CH A 90323256/93 CH F 19186611 CH F 1918667 DD C 11110788 DE A1 24236500 DK B 12668819 DK CC 10668819 ES A1 44466666/93 ES A1 44466666/93 ES A1 44466666/93 FI C 90323256/93 FR A1 22266677/93 FR B1 14172999/93 GB A 14966440/93 HU F 16966440/93 IL B 446615 IL AO 446615 IL A1 446615 JP A2 50040599/93 JP A2 57150699/93 JP B4 57058644/93 JP B4 58027279	29-04-77 00-09-77 08-08-76 08-08-76 12-04-77 12-04-77 11-11-75 06-06-77 11-10-77 11-10-77 01-07-79 01-07-79 00-01-75 05-12-74 08-11-77 16-08-78 01-07-76 01-07-76 01-09-76 01-09-76 10-09-79 10-10-75 26-07-75 17-12-75 18-01-76 08-12-76 08-08-76 10-02-75
			IL A1 446615 JP A2 50040599/93 JP A2 57150699/93 JP B4 57058644/93 JP B4 58027279	30-12-77 14-04-76 17-09-82 09-12-82 08-06-83



PCT/KR 96/00005

Form PCT/ISA/210 (patent family annex) (July 1992)